var title_f16_61_17360="Hydrocele PI";
var content_f16_61_17360=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F55941&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F55941&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 477px\">",
"   <div class=\"ttl\">",
"    Hydrocele",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 457px; height: 549px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A hydrocele is a sac of fluid that forms inside the scrotum around 1 of the testicles.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_61_17360=[""].join("\n");
var outline_f16_61_17360=null;
var title_f16_61_17361="Contents: Heart and blood vessel disease";
var content_f16_61_17361=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?18/22/18798\">",
"       Patient Information",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Heart and blood vessel disease",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Heart and blood vessel disease",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Abdominal aortic aneurysm",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/62/34787\">",
"           Patient information: Abdominal aortic aneurysm (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/39/22130\">",
"           Patient information: Abdominal aortic aneurysm (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Anticoagulation",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/11/14515\">",
"           Patient information: Latest medicines to prevent blood clots (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/43/28337\">",
"           Patient information: Prothrombin time (PT) test and International Normalized Ratio (INR) (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/15/21747\">",
"           Patient information: Warfarin (Coumadin) (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/44/2755\">",
"           Patient information: Warfarin (Coumadin) (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Aortic dissection",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/38/30307\">",
"           Patient information: Aortic dissection (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Atrial fibrillation",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/16/261\">",
"           Patient information: Atrial fibrillation (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/32/20994\">",
"           Patient information: Atrial fibrillation (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/57/1939\">",
"           Patient information: Heart failure and atrial fibrillation (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/11/14515\">",
"           Patient information: Latest medicines to prevent blood clots (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/36/17986\">",
"           Patient information: Medicines for atrial fibrillation (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/31/14834\">",
"           Patient information: Radiofrequency catheter ablation for the heart (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/54/13154\">",
"           Patient information: Radiofrequency catheter ablation for the heart (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Birth defects",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/43/41649\">",
"           Patient information: Aortic coarctation in adults (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/47/25329\">",
"           Patient information: Aortic coarctation in children (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/31/6642\">",
"           Patient information: Atrial septal defect (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/1/12306\">",
"           Patient information: Patent foramen ovale (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/25/2450\">",
"           Patient information: Tetralogy of Fallot (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/15/242\">",
"           Patient information: Total anomalous pulmonary venous connection in children (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/26/4514\">",
"           Patient information: Ventricular septal defect (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Blood vessels in the legs",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/17/35091\">",
"           Patient information: Chronic venous disease (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/35/14900\">",
"           Patient information: Peripheral artery disease and claudication (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/49/34578\">",
"           Patient information: Peripheral artery disease and claudication (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/16/21762\">",
"           Patient information: Superficial phlebitis (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/47/41714\">",
"           Patient information: Varicose veins and other vein disease in the legs (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/32/30210\">",
"           Patient information: Vein ablation (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Cardiac arrest",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/39/34419\">",
"           Patient information: Sudden cardiac arrest (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/12/25795\">",
"           Patient information: Ventricular fibrillation (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Cardiac tamponade",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/49/34577\">",
"           Patient information: Cardiac tamponade (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Cardiomyopathy",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/17/44305\">",
"           Patient information: Dilated cardiomyopathy (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/13/21714\">",
"           Patient information: Dilated cardiomyopathy (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/49/18197\">",
"           Patient information: Hypertrophic cardiomyopathy (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/28/35266\">",
"           Patient information: Hypertrophic cardiomyopathy in adults (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/24/36226\">",
"           Patient information: Hypertrophic cardiomyopathy in children (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/6/35938\">",
"           Patient information: Stress-induced cardiomyopathy (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Carotid artery disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/5/23635\">",
"           Patient information: Atherosclerosis (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/14/12512\">",
"           Patient information: Carotid artery disease (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Children and cardiovascular disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/35/4660\">",
"           Patient information: Children and heart disease (atherosclerosis) (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/24/36226\">",
"           Patient information: Hypertrophic cardiomyopathy in children (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/50/8995\">",
"           Patient information: Wolff-Parkinson-White syndrome (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/56/23427\">",
"           Patient information: Wolff-Parkinson-White syndrome (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Coronary heart disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/1/31766\">",
"           Patient information: Angina treatment ��������� medical therapy (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/10/43170\">",
"           Patient information: Angina treatment ��������� medical versus interventional therapy (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/24/39298\">",
"           Patient information: Angioplasty and stenting for the heart (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/54/40803\">",
"           Patient information: Aspirin and cardiovascular disease (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/5/23635\">",
"           Patient information: Atherosclerosis (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/56/24450\">",
"           Patient information: Can foods or supplements lower cholesterol? (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/9/43157\">",
"           Patient information: Chest pain (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/34/21027\">",
"           Patient information: Chest pain (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/62/31717\">",
"           Patient information: Coronary artery bypass graft surgery (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/10/27809\">",
"           Patient information: Coronary heart disease (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/54/7012\">",
"           Patient information: Coronary heart disease in women (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/30/5602\">",
"           Patient information: Familial hypercholesterolemia (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/16/40195\">",
"           Patient information: Heart attack (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/53/10068\">",
"           Patient information: Heart attack (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/52/12100\">",
"           Patient information: Heart attack recovery (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/6/37987\">",
"           Patient information: Heart attack recovery (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/38/18020\">",
"           Patient information: Heart stents and angioplasty (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/27/21940\">",
"           Patient information: Medicines after a heart attack (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/35/1587\">",
"           Patient information: Medicines for angina (chest pain) (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/16/23813\">",
"           Patient information: Recovery after coronary artery bypass graft surgery (CABG) (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/42/21156\">",
"           Patient information: Recovery after coronary artery bypass graft surgery (CABG) (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/14/30946\">",
"           Patient information: Treatment choices for angina (chest pain) (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/2/32803\">",
"           Patient information: What can go wrong after a heart attack? (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Endocarditis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/48/26370\">",
"           Patient information: Endocarditis (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Heart failure",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/34/37410\">",
"           Patient information: Cardiac resynchronization therapy (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/40/13956\">",
"           Patient information: Diastolic heart failure (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/5/33877\">",
"           Patient information: Heart failure (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/12/17601\">",
"           Patient information: Heart failure (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/57/1939\">",
"           Patient information: Heart failure and atrial fibrillation (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/5/92\">",
"           Patient information: Heart transplant (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/36/26179\">",
"           Patient information: Heart transplantation (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/41/36499\">",
"           Patient information: Medicines for heart failure (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/32/7684\">",
"           Patient information: Systolic heart failure (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/4/11331\">",
"           Patient information: When your lungs fill with fluid (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Heart murmurs",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/42/36514\">",
"           Patient information: Heart murmurs (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Heart valve disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/35/32306\">",
"           Patient information: Aortic regurgitation in adults (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/53/36690\">",
"           Patient information: Aortic stenosis (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/59/27575\">",
"           Patient information: Mitral regurgitation (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/60/19394\">",
"           Patient information: Mitral regurgitation (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/31/12787\">",
"           Patient information: Mitral stenosis in adults (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/4/21571\">",
"           Patient information: Mitral valve prolapse (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/23/11635\">",
"           Patient information: Prosthetic valves (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/36/33346\">",
"           Patient information: Tricuspid regurgitation (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/52/14146\">",
"           Patient information: Tricuspid stenosis (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         High blood pressure (hypertension)",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/56/40835\">",
"           Patient information: Controlling your blood pressure through lifestyle (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/57/27539\">",
"           Patient information: High blood pressure emergencies (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/54/33635\">",
"           Patient information: High blood pressure in adults (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/58/34722\">",
"           Patient information: High blood pressure in adults (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/32/37380\">",
"           Patient information: High blood pressure treatment in adults (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/8/9347\">",
"           Patient information: High blood pressure, diet, and weight (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/40/23171\">",
"           Patient information: Medicines for high blood pressure (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/61/39889\">",
"           Patient information: Pulmonary hypertension in adults (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/20/37186\">",
"           Patient information: Renovascular hypertension (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         High cholesterol",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/5/23635\">",
"           Patient information: Atherosclerosis (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/56/24450\">",
"           Patient information: Can foods or supplements lower cholesterol? (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/30/5602\">",
"           Patient information: Familial hypercholesterolemia (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/48/11011\">",
"           Patient information: High cholesterol (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/4/6212\">",
"           Patient information: High cholesterol and lipids (hyperlipidemia) (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/6/43108\">",
"           Patient information: High cholesterol treatment options (Beyond the Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         High triglycerides",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/28/20930\">",
"           Patient information: High triglycerides (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Irregular heartbeat (arrhythmia)",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/16/8451\">",
"           Patient information: Atrial flutter (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/46/8931\">",
"           Patient information: Bradycardia (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/10/24738\">",
"           Patient information: Cardioversion (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/26/44449\">",
"           Patient information: Heart block in adults (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/57/20369\">",
"           Patient information: Heart block in children (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/25/19859\">",
"           Patient information: Long QT syndrome (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/31/14834\">",
"           Patient information: Radiofrequency catheter ablation for the heart (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/54/13154\">",
"           Patient information: Radiofrequency catheter ablation for the heart (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/40/19075\">",
"           Patient information: Sick sinus syndrome (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/45/11986\">",
"           Patient information: Supraventricular tachycardia (SVT) (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/34/5666\">",
"           Patient information: Tachycardia (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/23/39281\">",
"           Patient information: Ventricular premature beats (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/51/27442\">",
"           Patient information: Ventricular tachycardia (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/50/8995\">",
"           Patient information: Wolff-Parkinson-White syndrome (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/56/23427\">",
"           Patient information: Wolff-Parkinson-White syndrome (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Low blood pressure (hypotension)",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/25/6546\">",
"           Patient information: Orthostatic hypotension (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Myocarditis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/14/15586\">",
"           Patient information: Myocarditis (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pacemakers and defibrillators",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/20/11589\">",
"           Patient information: Implantable cardioverter-defibrillators (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/60/38850\">",
"           Patient information: Implantable cardioverter-defibrillators (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/16/20741\">",
"           Patient information: Pacemakers (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/49/6931\">",
"           Patient information: Pacemakers (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pericarditis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/53/12115\">",
"           Patient information: Pericarditis (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/14/38113\">",
"           Patient information: Pericarditis in adults (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/56/11138\">",
"           Patient information: Pericarditis in children (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Raynaud disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/4/35905\">",
"           Patient information: Raynaud disease (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/49/30481\">",
"           Patient information: Raynaud phenomenon (Beyond the Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Shock",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/24/24961\">",
"           Patient information: Shock (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Stroke",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/61/30674\">",
"           Patient information: Aphasia (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/42/26274\">",
"           Patient information: Arteriovenous malformations in the brain (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/5/23635\">",
"           Patient information: Atherosclerosis (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/17/5394\">",
"           Patient information: Brain aneurysm (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/14/12512\">",
"           Patient information: Carotid artery disease (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/23/26994\">",
"           Patient information: Dysarthria (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/34/22050\">",
"           Patient information: Hemorrhagic stroke (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/63/8180\">",
"           Patient information: Hemorrhagic stroke treatment (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/53/19286\">",
"           Patient information: Ischemic stroke treatment (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/40/39554\">",
"           Patient information: Lowering the risk of having another stroke (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/37/36435\">",
"           Patient information: Medicines after an ischemic stroke (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/45/3795\">",
"           Patient information: Recovery after stroke (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/55/24435\">",
"           Patient information: Stroke (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/37/38484\">",
"           Patient information: Stroke symptoms and diagnosis (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/19/30002\">",
"           Patient information: Subarachnoid hemorrhage (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/18/20772\">",
"           Patient information: Transient ischemic attack (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/22/35170\">",
"           Patient information: Transient ischemic attack (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Syncope (fainting)",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/9/4245\">",
"           Patient information: Syncope (fainting) (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/5/36946\">",
"           Patient information: Syncope (fainting) (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Tests",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/53/35667\">",
"           Patient information: Cardiac catheterization (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/34/30242\">",
"           Patient information: Doppler ultrasound (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/51/25395\">",
"           Patient information: ECG and stress test (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/13/24787\">",
"           Patient information: Echocardiogram (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/30/32226\">",
"           Patient information: Nuclear heart testing (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/17/33042\">",
"           Patient information: Vagal maneuvers and their responses (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-25B1FF743F-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f16_61_17361=[""].join("\n");
var outline_f16_61_17361=null;
var title_f16_61_17362="PLAX view of nonclassic MVP";
var content_f16_61_17362=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1166px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/83602/PLAX_nonclassic_MVP_video.mp4?title=PLAX+view+of+nonclassic+MVP\" style=\"width:512px;height:400px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 534px\">",
"   <div class=\"ttl\">",
"    Parasternal long-axis echocardiographic view of nonclassic mitral valve prolapse with flail posterior leaflet",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 514px; height: 354px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Images from a patient with fibroelastic deficiency with flail P2 scallop. Note focal involvement of the middle posterior scallop.",
"    <div class=\"footnotes\">",
"     %: percent.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_61_17362=[""].join("\n");
var outline_f16_61_17362=null;
var title_f16_61_17363="Dicloxacillin: Pediatric drug information";
var content_f16_61_17363=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Dicloxacillin: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?3/11/3253?source=see_link\">",
"    see \"Dicloxacillin: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?2/14/2276?source=see_link\">",
"    see \"Dicloxacillin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1046999\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Penicillin (Antistaphylococcal)",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1046994\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?3/11/3253?source=see_link\">",
"      see \"Dicloxacillin: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &lt;40 kg: 25-50 mg/kg/day divided every 6 hours; doses of 50-100 mg/kg/day in divided doses every 6 hours have been used for follow-up therapy of osteomyelitis; maximum dose: 2 g/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &gt;40 kg and Adults: 125-500 mg every 6 hours; maximum dose: 2 g/day",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F159474\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral: 250 mg, 500 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F159459\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1047002\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer with water 1 hour before or 2 hours after meals on an empty stomach",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1047001\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of skin and soft tissue infections, pneumonia and follow-up therapy of osteomyelitis caused by susceptible penicillinase-producing staphylococci",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F159530\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, diarrhea, nausea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Agranulocytosis, eosinophilia, hemolytic anemia, hepatotoxicity, hypersensitivity, interstitial nephritis, leukopenia, neutropenia, prolonged PT, pseudomembranous colitis, rash (maculopapular to exfoliative), seizure with extremely high doses and/or renal failure, serum sickness-like reactions, thrombocytopenia, vaginitis, vomiting",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1047005\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to dicloxacillin, penicillin, or any component",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1046993\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Elimination is prolonged in neonates",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F159519\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Induces",
"     </b>",
"     CYP3A4 (weak/moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F159468\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.  Management: Double the oral aripiprazole dose and closely monitor clinical response.  Reduce the oral aripiprazole dose to 10-15 mg/day if the inducer is discontinued. Avoid use of CYP3A4 inducers for more than 14 days with extended-release injectable aripiprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inducers (Weakly to Moderately Effective) may decrease the serum concentration of Axitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fusidic Acid: May diminish the therapeutic effect of Penicillins.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Penicillins may increase the serum concentration of Methotrexate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: Penicillins may decrease serum concentrations of the active metabolite(s) of Mycophenolate. This effect appears to be the result of impaired enterohepatic recirculation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Penicillins.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inducers may decrease the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: May diminish the therapeutic effect of Penicillins.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Dicloxacillin may diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Penicillins may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1047007\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food decreases the rate and extent of absorption",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F159470\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5720683\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have not been observed in animal studies; therefore, dicloxacillin is classified as pregnancy category B.  Dicloxacillin crosses the placenta. Teratogenic effects have not been reported with dicloxacillin, but adequate and well-controlled studies of dicloxacillin have not been completed in pregnant women. Other penicillins are considered safe for use in pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1046998\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Periodic monitoring of CBC, platelet count, BUN, serum creatinine, urinalysis, and liver enzymes during prolonged therapy",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1046992\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins and interfering with the final transpeptidation step of peptidoglycan synthesis",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1047004\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: 35% to 76% absorbed from the GI tract",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Into bone, bile, pleural fluid, synovial fluid, and amniotic fluid; appears in breast milk",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 96% to 98%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: Adults: 0.6-0.8 hours; slightly prolonged in patients with renal impairment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Within 0.5-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Partially eliminated by the liver and excreted in bile; 31% to 65% eliminated in urine as unchanged drug and active metabolite",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neonates: Prolonged",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CF patients: More rapid elimination than healthy patients",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Not dialyzable (0% to 5%)",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1047006\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Sodium content of 250 mg capsule: 0.6 mEq",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13227 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-199.231.185.123-BA1283B04E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_61_17363=[""].join("\n");
var outline_f16_61_17363=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046999\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046994\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159474\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159459\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047002\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047001\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159530\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047005\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046993\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159519\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159468\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047007\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159470\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5720683\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046998\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046992\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047004\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047006\">",
"      Additional Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13227\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13227|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?3/11/3253?source=related_link\">",
"      Dicloxacillin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?2/14/2276?source=related_link\">",
"      Dicloxacillin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_61_17364="Acanthosis nigricans neck";
var content_f16_61_17364=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F64585&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F64585&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acanthosis nigricans",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 420px; height: 334px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Velvety, hyperpigmented plaques are present on the neck of this patient with acanthosis nigricans.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart, HP. Goodheart's Photoguide of Common Skin Disorders, 2nd Edition, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_61_17364=[""].join("\n");
var outline_f16_61_17364=null;
var title_f16_61_17365="Pitavastatin: Patient drug information";
var content_f16_61_17365=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Pitavastatin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/56/9095?source=see_link\">",
"     see \"Pitavastatin: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8101006\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Livalo&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10022430\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10022432\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691407",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower cholesterol and other harmful types of cholesterol in the body. Good cholesterol (HDL) levels rise.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691358",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower triglycerides.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10022431\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702750",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to pitavastatin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703199",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Active liver disease or a rise in liver enzymes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10022436\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid or limit drinking wine, beer, or mixed drinks to less than 3 drinks a day. Drinking too much alcohol may raise your chance of liver disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10022437\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697883",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Back pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698255",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Muscle weakness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698195",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Joint pain.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10022439\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699038",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad muscle pain or weakness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698663",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flu-like signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10022434\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10022435\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10022440\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10022441\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12293 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-0AA24E0359-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_61_17365=[""].join("\n");
var outline_f16_61_17365=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8101006\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022430\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022432\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022431\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022436\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022437\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022439\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022434\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022435\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022440\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022441\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?8/56/9095?source=related_link\">",
"      Pitavastatin: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_61_17366="Lip-licking dermatitis";
var content_f16_61_17366=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F54887&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F54887&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Lip-licking dermatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lip-licking dermatitis is a chronic irritant contact dermatitis caused by repeated exposure to saliva of lips and perioral area. Erythema with hyperpigmentation, scaling, and fissures form a well-demarcated ring around the lips.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_61_17366=[""].join("\n");
var outline_f16_61_17366=null;
var title_f16_61_17367="Emergency airway management in children: Unique pediatric considerations";
var content_f16_61_17367=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Emergency airway management in children: Unique pediatric considerations",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/61/17367/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/61/17367/contributors\">",
"     Joshua Nagler, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/61/17367/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/61/17367/contributors\">",
"     Anne M Stack, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/61/17367/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/61/17367/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/61/17367/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of the infant and pediatric airway can pose unique challenges. Anatomic features of a child's head, neck, and airway, as well as physiologic differences between children and adults, must be considered. Recognizing and addressing these pediatric-specific attributes are important in equipment selection, patient positioning, and airway management technique.",
"   </p>",
"   <p>",
"    The anatomic structures and physiologic processes that affect the assessment and management of the airway in children will be reviewed here as will the challenge of achieving proficiency for practitioners who infrequently perform pediatric airway management. Specifics regarding airway management techniques are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/22/29030?source=see_link\">",
"     \"Basic airway management in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/48/29450?source=see_link\">",
"     \"Emergent endotracheal intubation in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/29/24026?source=see_link\">",
"     \"Rapid sequence intubation (RSI) in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANATOMIC CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several anatomic features in infants and children that may impact advanced airway management. Here we discuss the relevant structures and their effect on airway management.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Prominent occiput",
"    </span>",
"    &nbsp;&mdash;&nbsp;The proportionally larger occiput in infants and younger children causes varying degrees of neck flexion in the supine position. This can result in anatomic airway obstruction or interfere with attempts to visualize the glottic opening during laryngoscopy. Placing a towel roll under the shoulders can improve airway alignment (",
"    <a class=\"graphic graphic_picture graphicRef78446 \" href=\"UTD.htm?33/4/33857\">",
"     picture 1",
"    </a>",
"    ). This approach is in contrast to placing a pad under the occiput in adults.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Large tongue",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants and young children have large tongues relative to the size of the oral cavity. Therefore, inadequate control and displacement of the tongue may impede visualization of the deeper airway during direct laryngoscopy. In addition, the tongue becomes a common source of upper airway obstruction, particularly in patients with depressed mental status and concomitant loss of intrinsic airway tone. Retroglossal obstruction occurs in approximately half of obstructions in infants, compared with adults where the vast majority of intrinsic airway obstruction occurs at the level of the soft palate [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17367/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Larger tonsils and adenoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children more commonly have larger tonsils and adenoids than adults. Studies utilizing magnetic resonance imaging (MRI) have confirmed that this increased mass of lymphoid tissue contributes to airway obstruction in children [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17367/abstract/3\">",
"     3",
"    </a>",
"    ]. In addition, adenoidal bleeding can occur with placement of a nasopharyngeal airway or attempts at nasotracheal intubation. Resultant blood in the naso- and hypopharynx can lead to aspiration and make glottic visualization challenging.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Superior laryngeal position",
"    </span>",
"    &nbsp;&mdash;&nbsp;The position of the larynx in infants and children is more cephalad than in adults. It is located opposite the C3 to C4 vertebrae, compared with the C4 to C5 in adults (",
"    <a class=\"graphic graphic_figure graphicRef50850 \" href=\"UTD.htm?10/20/10563\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef62656 \" href=\"UTD.htm?31/27/32179\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17367/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. This creates a more acute angle between the glottic opening and the base of the tongue, which can make direct visualization more challenging.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Weaker hyoepiglottic ligament",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hyoepiglottic ligament runs at the base of the vallecula, attaching the epiglottis to the base of the tongue. In young children, it has less tensile strength; therefore curved blades designed for tip placement in the vallecula (eg, Macintosh) may not elevate the epiglottis as effectively as in adults.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Large, floppy epiglottis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The epiglottis is relatively large and floppy in children, particularly those younger than three years of age. It is also angled more acutely with respect to the axis of the trachea. As a result, the epiglottis projects into the airway and covers more of the glottic aperture (",
"    <a class=\"graphic graphic_figure graphicRef50850 \" href=\"UTD.htm?10/20/10563\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef62656 \" href=\"UTD.htm?31/27/32179\">",
"     figure 2",
"    </a>",
"    ). Effective mobilization of the epiglottis also favors the use of a straight blade to directly lift the epiglottis for improved visualization during direct laryngoscopy (",
"    <a class=\"graphic graphic_figure graphicRef70746 \" href=\"UTD.htm?14/28/14790\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Shorter trachea",
"    </span>",
"    &nbsp;&mdash;&nbsp;The trachea increases in length with age, from approximately 5 cm in neonates to 12 cm in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17367/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. The short trachea predisposes to right mainstem bronchus intubation or inadvertent extubation, given the short segment within which an endotracheal tube (ETT) can be correctly placed. This can occur at the time of intubation, or during unintentional head movement, which has been shown to displace ETTs as much as 1 cm in neonates and 2 cm in older children [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17367/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Narrow trachea",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to being shorter, the trachea in younger children is also narrow [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17367/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Because airway resistance is inversely proportional to the lumen radius to the fourth power, even small decreases in the airway size from secretions, edema, or external compression (including cricoid pressure, in circumstances in which it is felt to be beneficial) will have disproportionate effects on these smaller airways (",
"    <a class=\"graphic graphic_figure graphicRef66343 \" href=\"UTD.htm?15/11/15538\">",
"     figure 4",
"    </a>",
"    ). The narrow tracheal lumen, combined with the narrow space between tracheal rings and small size of the cricothyroid membranes, makes needle or surgical cricothyroidotomy technically challenging in infants and children [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17367/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/7/15481?source=see_link\">",
"     \"The difficult pediatric airway\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Anatomic subglottic narrowing",
"    </span>",
"    &nbsp;&mdash;&nbsp;In adults, the vocal cords comprise the narrowest portion of the airway. The cricoid ring has been identified as the narrowest portion of the pediatric airway in historic cadaveric studies [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17367/abstract/10\">",
"     10",
"    </a>",
"    ]. Newer data from anesthetized children suggest anatomic narrowing may be greatest at the vocal cords though the elliptical cross sectional shape of the subglottis and the non-distensible cricoid cartilage in the spontaneously breathing child still make the subglottic region functionally the narrowest [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17367/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As a result of the subglottic narrowing, foreign bodies can become lodged below the cords, or the endotracheal tube (ETT) may be small enough to pass through the cords but not beyond the cricoid ring. Importantly, this narrowing can create an effective anatomic seal without the need for a cuffed ETT. With the advent of newer, smaller profile, lower pressure cuffed tubes, however, the American Heart Association now has approved cuffed ETTs for all pediatric patients outside the newborn period, provided the cuff pressure can be maintained at less than 20 cm H20 [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17367/abstract/13\">",
"     13",
"    </a>",
"    ]. In addition, use of a cuffed ETT in children is associated with a reduced need for ETT exchanges and no increase in post-extubation morbidity when compared to uncuffed tubes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/48/29450?source=see_link&amp;anchor=H1618840#H1618840\">",
"     \"Emergent endotracheal intubation in children\", section on 'Cuffed versus uncuffed'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Compliant chest wall",
"    </span>",
"    &nbsp;&mdash;&nbsp;The thoracic skeleton in children is primarily cartilaginous and therefore more compliant than the ossified bony structures in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17367/abstract/14\">",
"     14",
"    </a>",
"    ]. Intrinsic muscle tone is required to maintain lung volumes and prevent chest wall distortion. Therefore, infants and young children are more likely to experience respiratory muscle fatigue, atelectasis and respiratory failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     PHYSIOLOGIC CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Age-specific physiologic features in infants and children can also affect advanced airway management. Here we discuss those processes which are different in children, and how they impact assessment and management of the pediatric airway.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Age-related respiratory rate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normative ranges for vital signs vary by age (",
"    <a class=\"graphic graphic_table graphicRef78097 \" href=\"UTD.htm?27/37/28252\">",
"     table 1",
"    </a>",
"    ). Variation in patterns may also occur, such as periodic breathing which occurs commonly in the first six months of life [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17367/abstract/15\">",
"     15",
"    </a>",
"    ]. Discriminating normal from concerning vital sign values and trends is paramount in assessing respiratory illness and response to therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Preferential nasal breathing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants are commonly believed to be obligate nasal breathers. Some data suggest that a subset of infants will fail to initiate mouth breathing within a prescribed time after nasal occlusion [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17367/abstract/16\">",
"     16",
"    </a>",
"    ]; however, others have shown infants can breathe through their mouths spontaneously or following nasal airflow obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17367/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. For the majority of infants who are nasal breathers, the nares account for nearly half the total airway resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17367/abstract/19\">",
"     19",
"    </a>",
"    ]. Therefore, obstruction by secretions, edema, or compression from non-flowing nasal cannula or a misplaced face mask can lead to significant increase in the work of breathing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Smaller tidal volumes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants and young children have small, relatively fixed tidal volumes relative to body size (6 to 8",
"    <span class=\"nowrap\">",
"     mL/kg).",
"    </span>",
"    As a result, they are susceptible to iatrogenic barotrauma from aggressive positive pressure ventilation. In addition, the limited ability to increase minute ventilation with deeper breathing means that any compensatory response to physiologic demands for increased minute volume is most likely to be manifest as tachypnea. Limited sustainability of rapid respiratory rates predisposes young infants to respiratory failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Lower functional residual capacity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Functional residual capacity (FRC) increases with age during childhood [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17367/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Therefore, young children have little intrapulmonary oxygen stores to utilize during hypoventilatory or apneic periods. Apneic infants, in particular, have a more precipitous decline in oxygen saturation, for example, when they undergo rapid sequence intubation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17367/abstract/22\">",
"     22",
"    </a>",
"    ]. For this reason, children have a heightened need for preoxygenation and, possibly, bag-mask ventilation during rapid sequence induction for intubation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/29/24026?source=see_link&amp;anchor=H4#H4\">",
"     \"Rapid sequence intubation (RSI) in children\", section on 'Preoxygenation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Higher oxygen metabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants have a higher metabolic rate and consume oxygen at a rate twice that of adults (6 versus 3",
"    <span class=\"nowrap\">",
"     mL/kg/min)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17367/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. This higher oxygen consumption, coupled with the lower FRC in children, results in a shorter safe apnea time. In a study of preoxygenated ASA I children (ie, healthy, no medical problems), the mean time to oxygen desaturation to 90 percent ranged from 1.5 minutes in children less than six months to more than six minutes in children greater than 11 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17367/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Prone to respiratory fatigue",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants and younger children have a lower percentage of efficient, slow-twitch (type 1) skeletal muscle fibers in their intercostal muscles than older patients [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17367/abstract/23\">",
"     23",
"    </a>",
"    ]. Therefore, when children utilize retractions to facilitate airflow during respiratory distress, they are more prone to fatigue, and ultimately, respiratory failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Higher vagal tone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants and young children may have a pronounced vagal response to laryngoscopy or airway suctioning. Because hypoxia potentiates the risk for bradycardia, efforts to maintain oxygenation before and during endotracheal intubation should be maximized.",
"   </p>",
"   <p>",
"    The role for",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/13/25816?source=see_link\">",
"     atropine",
"    </a>",
"    in preventing bradycardia during airway management is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/29/24026?source=see_link&amp;anchor=H12#H12\">",
"     \"Rapid sequence intubation (RSI) in children\", section on 'Atropine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     LIMITED OPPORTUNITY TO GAIN PROFICIENCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laryngoscopy and endotracheal intubation are complex psychomotor skills that require sufficient training and practice to achieve and maintain proficiency. Studies including neonatal, pediatric, and adult populations have shown that intubation success increases by level of training [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17367/abstract/24-27\">",
"     24-27",
"    </a>",
"    ]. As an example, in an observational study that evaluated first-time success rates for 114 pediatric rapid sequence intubations in children&rsquo;s hospital emergency departments, pediatric emergency medicine attendings had a higher first-time success rate (89 percent) than pediatric emergency medicine fellows (43 percent) or pediatric residents (35 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17367/abstract/27\">",
"     27",
"    </a>",
"    ]. More specifically, learning curves for anesthesia resident clinicians in a controlled setting showed that after 10 intubations the success rate was less than 50 percent, and only after 57 intubations did these trainees achieve a 90 percent success rate [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17367/abstract/28\">",
"     28",
"    </a>",
"    ]. For non-anesthesia trainees, success also increased with experience, with a predicted 90 percent rate of \"good\" intubations achieved after 47 prior attempts [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17367/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In pediatrics, advanced airway management experience for many providers outside of anesthesia may be limited. Comparing data from pediatric and adult tertiary care emergency departments, health care providers have less frequent opportunities to perform intubation in children than in adults. A survey of pediatric emergency departments suggests a range of 1.1 to 3.3 intubations per 1000 patients per year [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17367/abstract/30\">",
"     30",
"    </a>",
"    ], while studies based in adult facilities demonstrate 6 to 10 intubations per 1000 patients per year [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17367/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. This demonstrated need for extensive experience, in contrast to the infrequent opportunities to perform advanced airway techniques in children, also needs to be considered in pediatric airway management. Simulation training can provide an alternative means for pediatric airway management training.",
"   </p>",
"   <p>",
"    Rescue ventilation devices such as the laryngeal mask airway, esophageal-tracheal combination tube (Combitube&reg;), or laryngeal tube provide alternatives to endotracheal intubation, and are more likely to be placed correctly than endotracheal tubes by providers with limited prior experience [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17367/abstract/33-40\">",
"     33-40",
"    </a>",
"    ]. Thus, health care providers who will be involved in airway management should develop comfort and familiarity with at least one rescue ventilation device. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/45/37593?source=see_link\">",
"     \"Emergency rescue devices for difficult pediatric airway management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the indications for airway management in children are similar to those in adults, unique pediatric anatomy and physiology create specific challenges in assessment and management:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anatomic structures in children predispose them to airway obstruction and significantly impact pediatric airway management. For example, the larger oropharyngeal structures (tongue, tonsils, and adenoids) and the large floppy epiglottis lead to greater difficulty in visualizing the vocal cords during laryngoscopy. Also, the shorter and narrower trachea predisposes to endotracheal tube malposition after intubation. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Anatomic considerations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Infants and children become hypoxemic more quickly than adults because of decreased functional residual capacity and increased oxygen consumption. These physiologic differences result in a shorter and less safe apnea time during rapid sequence intubation (RSI), emphasizing the need for adequate preoxygenation and occasionally, bag-mask ventilation during RSI. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Physiologic considerations'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/29/24026?source=see_link\">",
"       \"Rapid sequence intubation (RSI) in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Developing competence and maintaining proficiency with advanced airway management is particularly challenging in children because of the relative infrequency with which most practitioners utilize these skills. Simulation training can provide an alternative means for airway management training. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Limited opportunity to gain proficiency'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17367/abstract/1\">",
"      Don GW, Kirjavainen T, Broome C, et al. Site and mechanics of spontaneous, sleep-associated obstructive apnea in infants. J Appl Physiol 2000; 89:2453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17367/abstract/2\">",
"      Eastwood PR, Szollosi I, Platt PR, Hillman DR. Collapsibility of the upper airway during anesthesia with isoflurane. Anesthesiology 2002; 97:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17367/abstract/3\">",
"      Arens R, McDonough JM, Costarino AT, et al. Magnetic resonance imaging of the upper airway structure of children with obstructive sleep apnea syndrome. Am J Respir Crit Care Med 2001; 164:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17367/abstract/4\">",
"      Westhorpe RN. The position of the larynx in children and its relationship to the ease of intubation. Anaesth Intensive Care 1987; 15:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17367/abstract/5\">",
"      Schwartz DS, Keller MS. Maturational descent of the epiglottis. Arch Otolaryngol Head Neck Surg 1997; 123:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17367/abstract/6\">",
"      Fearon B, Whalen JS. Tracheal dimensions in the living infant (preliminary report). Ann Otol Rhinol Laryngol 1967; 76:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17367/abstract/7\">",
"      Griscom NT, Wohl ME. Dimensions of the growing trachea related to age and gender. AJR Am J Roentgenol 1986; 146:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17367/abstract/8\">",
"      Weiss M, Knirsch W, Kretschmar O, et al. Tracheal tube-tip displacement in children during head-neck movement--a radiological assessment. Br J Anaesth 2006; 96:486.",
"     </a>",
"    </li>",
"    <li>",
"     American College of Surgeons Committee on Trauma. Advanced Trauma Life Support for Doctors, 8th ed, American College of Surgeons, Chicago 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17367/abstract/10\">",
"      ECKENHOFF JE. Some anatomic considerations of the infant larynx influencing endotracheal anesthesia. Anesthesiology 1951; 12:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17367/abstract/11\">",
"      Litman RS, Weissend EE, Shibata D, Westesson PL. Developmental changes of laryngeal dimensions in unparalyzed, sedated children. Anesthesiology 2003; 98:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17367/abstract/12\">",
"      Dalal PG, Murray D, Messner AH, et al. Pediatric laryngeal dimensions: an age-based analysis. Anesth Analg 2009; 108:1475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17367/abstract/13\">",
"      Kleinman ME, Chameides L, Schexnayder SM, et al. Part 14: pediatric advanced life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2010; 122:S876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17367/abstract/14\">",
"      Papastamelos C, Panitch HB, England SE, Allen JL. Developmental changes in chest wall compliance in infancy and early childhood. J Appl Physiol 1995; 78:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17367/abstract/15\">",
"      Kelly DH, Stellwagen LM, Kaitz E, Shannon DC. Apnea and periodic breathing in normal full-term infants during the first twelve months. Pediatr Pulmonol 1985; 1:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17367/abstract/16\">",
"      Swift PG, Emery JL. Clinical observations on response to nasal occlusion in infancy. Arch Dis Child 1973; 48:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17367/abstract/17\">",
"      Miller MJ, Martin RJ, Carlo WA, et al. Oral breathing in newborn infants. J Pediatr 1985; 107:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17367/abstract/18\">",
"      Rodenstein DO, Perlmutter N, St��nescu DC. Infants are not obligatory nasal breathers. Am Rev Respir Dis 1985; 131:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17367/abstract/19\">",
"      Stocks J, Godfrey S. Nasal resistance during infancy. Respir Physiol 1978; 34:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17367/abstract/20\">",
"      Gerhardt T, Reifenberg L, Hehre D, et al. Functional residual capacity in normal neonates and children up to 5 years of age determined by a N2 washout method. Pediatr Res 1986; 20:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17367/abstract/21\">",
"      Stocks J, Quanjer PH. Reference values for residual volume, functional residual capacity and total lung capacity. ATS Workshop on Lung Volume Measurements. Official Statement of The European Respiratory Society. Eur Respir J 1995; 8:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17367/abstract/22\">",
"      Patel R, Lenczyk M, Hannallah RS, McGill WA. Age and the onset of desaturation in apnoeic children. Can J Anaesth 1994; 41:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17367/abstract/23\">",
"      Keens TG, Bryan AC, Levison H, Ianuzzo CD. Developmental pattern of muscle fiber types in human ventilatory muscles. J Appl Physiol 1978; 44:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17367/abstract/24\">",
"      Sagarin MJ, Barton ED, Chng YM, et al. Airway management by US and Canadian emergency medicine residents: a multicenter analysis of more than 6,000 endotracheal intubation attempts. Ann Emerg Med 2005; 46:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17367/abstract/25\">",
"      Sagarin MJ, Chiang V, Sakles JC, et al. Rapid sequence intubation for pediatric emergency airway management. Pediatr Emerg Care 2002; 18:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17367/abstract/26\">",
"      Leone TA, Rich W, Finer NN. Neonatal intubation: success of pediatric trainees. J Pediatr 2005; 146:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17367/abstract/27\">",
"      Kerrey BT, Rinderknecht AS, Geis GL, et al. Rapid sequence intubation for pediatric emergency patients: higher frequency of failed attempts and adverse effects found by video review. Ann Emerg Med 2012; 60:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17367/abstract/28\">",
"      Konrad C, Sch&uuml;pfer G, Wietlisbach M, Gerber H. Learning manual skills in anesthesiology: Is there a recommended number of cases for anesthetic procedures? Anesth Analg 1998; 86:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17367/abstract/29\">",
"      Mulcaster JT, Mills J, Hung OR, et al. Laryngoscopic intubation: learning and performance. Anesthesiology 2003; 98:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17367/abstract/30\">",
"      Losek JD, Olson LR, Dobson JV, Glaeser PW. Tracheal intubation practice and maintaining skill competency: survey of pediatric emergency department medical directors. Pediatr Emerg Care 2008; 24:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17367/abstract/31\">",
"      Levitan RM, Everett WW, Ochroch EA. Limitations of difficult airway prediction in patients intubated in the emergency department. Ann Emerg Med 2004; 44:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17367/abstract/32\">",
"      Sakles JC, Laurin EG, Rantapaa AA, Panacek EA. Airway management in the emergency department: a one-year study of 610 tracheal intubations. Ann Emerg Med 1998; 31:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17367/abstract/33\">",
"      Chen L, Hsiao AL. Randomized trial of endotracheal tube versus laryngeal mask airway in simulated prehospital pediatric arrest. Pediatrics 2008; 122:e294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17367/abstract/34\">",
"      Davis DP, Valentine C, Ochs M, et al. The Combitube as a salvage airway device for paramedic rapid sequence intubation. Ann Emerg Med 2003; 42:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17367/abstract/35\">",
"      Guyette FX, Roth KR, LaCovey DC, Rittenberger JC. Feasibility of laryngeal mask airway use by prehospital personnel in simulated pediatric respiratory arrest. Prehosp Emerg Care 2007; 11:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17367/abstract/36\">",
"      Kette F, Reffo I, Giordani G, et al. The use of laryngeal tube by nurses in out-of-hospital emergencies: preliminary experience. Resuscitation 2005; 66:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17367/abstract/37\">",
"      Kurola J, Pere P, Niemi-Murola L, et al. Comparison of airway management with the intubating laryngeal mask, laryngeal tube and CobraPLA by paramedical students in anaesthetized patients. Acta Anaesthesiol Scand 2006; 50:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17367/abstract/38\">",
"      Kurola JO, Turunen MJ, Laakso JP, et al. A comparison of the laryngeal tube and bag-valve mask ventilation by emergency medical technicians: a feasibility study in anesthetized patients. Anesth Analg 2005; 101:1477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17367/abstract/39\">",
"      Russi CS, Miller L, Hartley MJ. A comparison of the King-LT to endotracheal intubation and Combitube in a simulated difficult airway. Prehosp Emerg Care 2008; 12:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17367/abstract/40\">",
"      Russi CS, Wilcox CL, House HR. The laryngeal tube device: a simple and timely adjunct to airway management. Am J Emerg Med 2007; 25:263.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6310 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-A7B94B43F3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_61_17367=[""].join("\n");
var outline_f16_61_17367=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANATOMIC CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Prominent occiput",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Large tongue",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Larger tonsils and adenoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Superior laryngeal position",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Weaker hyoepiglottic ligament",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Large, floppy epiglottis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Shorter trachea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Narrow trachea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Anatomic subglottic narrowing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Compliant chest wall",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      PHYSIOLOGIC CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Age-related respiratory rate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Preferential nasal breathing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Smaller tidal volumes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Lower functional residual capacity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Higher oxygen metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Prone to respiratory fatigue",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Higher vagal tone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      LIMITED OPPORTUNITY TO GAIN PROFICIENCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6310\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6310|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/20/10563\" title=\"figure 1\">",
"      Child vs adult airway 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/27/32179\" title=\"figure 2\">",
"      Child vs adult airway 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/28/14790\" title=\"figure 3\">",
"      Laryngoscopy child",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/11/15538\" title=\"figure 4\">",
"      Airway resistance child",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6310|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/4/33857\" title=\"picture 1\">",
"      Prominent occiput with pediatric airway obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6310|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/37/28252\" title=\"table 1\">",
"      Normal respiratory rate and heart rate in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/22/29030?source=related_link\">",
"      Basic airway management in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/45/37593?source=related_link\">",
"      Emergency rescue devices for difficult pediatric airway management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/48/29450?source=related_link\">",
"      Emergent endotracheal intubation in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/29/24026?source=related_link\">",
"      Rapid sequence intubation (RSI) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/7/15481?source=related_link\">",
"      The difficult pediatric airway",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_61_17368="Langerhans histiocytosis CT I";
var content_f16_61_17368=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F58182%7EPULM%2F69891%7EPULM%2F72698&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F58182%7EPULM%2F69891%7EPULM%2F72698&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cystic changes in Langerhans cell histiocytosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 377px; height: 204px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Langerhans cell histiocytosis (eosinophilic granuloma) in an adolescent boy characterized by multiple cysts in the upper and lower lobes. The cysts are interspersed throughout the parenchyma and have a slightly thick wall. A posterior right upper lobe nodule and confluent bibasilar patchy lower lobe opacities are also part of the disease process.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cystic changes in Langerhans cell histiocytosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 364px; height: 225px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Langerhans cell pulmonary histiocytosis (eosinophilic granuloma) in an adolescent boy characterized by multiple cysts in the upper and lower lobes. The cysts are interspersed throughout the parenchyma and have a slightly thick wall. A posterior right upper lobe nodule and confluent bibasilar patchy lower lobe opacities are also part of the disease process.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pulmonary Langerhans cell histiocytosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 304px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    High resolution CT with thin section shows the cysts in pulmonary LCH, which vary markedly in size and may be larger than 10 mm. The cysts are bizarre in shape,&nbsp;often closely related to pulmonary arteries, and mimic bronchiectasis. Few nodules are present in this case.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Talmadge E King Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_61_17368=[""].join("\n");
var outline_f16_61_17368=null;
var title_f16_61_17369="Pityriasis lichenoides et varioliformis acuta (PLEVA)";
var content_f16_61_17369=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pityriasis lichenoides et varioliformis acuta (PLEVA)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/61/17369/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/61/17369/contributors\">",
"     James R Treat, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/61/17369/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/61/17369/contributors\">",
"     Moise L Levy, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/61/17369/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/61/17369/contributors\">",
"     Abena O Ofori, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/61/17369/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H8868209\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pityriasis lichenoides et varioliformis acuta (PLEVA), otherwise known as Mucha-Habermann disease, is an uncommon cutaneous inflammatory disorder that most frequently affects young adults and children. PLEVA usually presents as an acute eruption of inflammatory papules and papulovesicles that rapidly develop hemorrhagic or necrotic crusts (",
"    <a class=\"graphic graphic_picture graphicRef57911 graphicRef83096 graphicRef85773 \" href=\"UTD.htm?24/26/25002\">",
"     picture 1A-C",
"    </a>",
"    ). Febrile ulceronecrotic Mucha-Habermann disease (FUMHD) is a potentially life-threatening, severe presentation of PLEVA.",
"   </p>",
"   <p>",
"    Pityriasis lichenoides chronica (PLC), which is characterized by the appearance of multiple scaly, red-brown papules on the skin, is often considered to be on a disease continuum with PLEVA (",
"    <a class=\"graphic graphic_picture graphicRef71210 \" href=\"UTD.htm?18/50/19233\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17369/abstract/1\">",
"     1",
"    </a>",
"    ]. The term &ldquo;pityriasis lichenoides&rdquo; is frequently used to refer to the spectrum of these disorders.",
"   </p>",
"   <p>",
"    The clinical features, diagnosis, and management of PLEVA will be discussed here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8868216\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;PLEVA is a rare disorder. The precise incidence and prevalence are not known. PLEVA may occur at any age (including infants) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17369/abstract/2\">",
"     2",
"    </a>",
"    ], but most frequently occurs in children and young adults.",
"   </p>",
"   <p>",
"    Data on PLEVA and PLC are often combined in the literature under pityriasis lichenoides, complicating the assessment of the epidemiology of PLEVA. A slight male predominance has been detected among children with pityriasis lichenoides [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17369/abstract/1\">",
"     1",
"    </a>",
"    ], and in one of the largest series of children with pityriasis lichenoides, 40 of 71 children with PLEVA (56 percent) were male [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17369/abstract/3\">",
"     3",
"    </a>",
"    ]. A male predominance is less consistently observed in the general population of patients with pityriasis lichenoides [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17369/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar to the classic presentation of PLEVA, the severe FUMHD variant primarily occurs in children and young adults. A 2008 review of 40 reported cases found that the mean age of affected patients was 27 (range 4 to 82 years) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17369/abstract/4\">",
"     4",
"    </a>",
"    ]. The majority of patients (75 percent) were under the age of 35 years.",
"   </p>",
"   <p>",
"    A separate review of 24 published cases of FUMHD found that seven of the reported patients were of Mediterranean descent and six patients were of Asian descent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17369/abstract/5\">",
"     5",
"    </a>",
"    ]. However, ethnic or geographic differences in the prevalence of PLEVA and FUMHD have not been definitively established.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8868223\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of PLEVA is poorly understood. The two prevailing pathogenic theories involve the classification of PLEVA as a T cell dyscrasia and the designation of PLEVA as an aberrant immune response to viral, bacterial, or protozoal infections.",
"   </p>",
"   <p>",
"    The identification of T cell clones in patients with PLEVA, the clinical resemblance of PLEVA to lymphomatoid papulosis, and the rare development of lymphoma in patients with PLEVA are used to support the concept that PLEVA and FUMHD may be T cell lymphoproliferative disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17369/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. In one study of patients with PLEVA, a dominant T cell clone was detected in 13 of 20 biopsy specimens [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17369/abstract/7\">",
"     7",
"    </a>",
"    ]. Based upon this theory, an immune response that attacks and eventually eliminates the T-cell clone could account for the self-limited disease course that typically characterizes PLEVA. (See",
"    <a class=\"local\" href=\"#H1433461\">",
"     'Disease course'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The assertion that PLEVA represents a hypersensitivity reaction to infectious agents arises from multiple reports of the development of PLEVA in the setting of recent or concurrent infections. Examples include infections due to",
"    <em>",
"     Toxoplasma gondii",
"    </em>",
"    , human herpesvirus 8, Epstein-Barr virus, human immunodeficiency virus, varicella-zoster virus, and group A",
"    <em>",
"     Streptococcus",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17369/abstract/9-15\">",
"     9-15",
"    </a>",
"    ]. In accordance with this theory, the detection of T cell clones in PLEVA could represent a clonal immunologic response to a microbial antigen, rather than a primary lymphoproliferative disease.",
"   </p>",
"   <p>",
"    An interesting observation is the detection of elevated levels of the proinflammatory cytokine tumor necrosis factor (TNF)-alpha and the soluble interleukin-2 receptor (a marker of elevated T cell activation) in patients with FUMHD [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17369/abstract/5,6,16\">",
"     5,6,16",
"    </a>",
"    ]. The relevance of these findings in the pathogenesis FUMHD remains to be determined.",
"   </p>",
"   <p>",
"    Several exogenously administered substances have been linked to the development of features consistent with PLEVA in case reports, such as tegafur, astemizole, estrogen-progesterone, and radiocontrast iodide [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17369/abstract/17-20\">",
"     17-20",
"    </a>",
"    ]. The mechanisms through which these substances might induce PLEVA are unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8868230\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1433285\">",
"    <span class=\"h2\">",
"     PLEVA",
"    </span>",
"    &nbsp;&mdash;&nbsp;PLEVA usually begins as an acute eruption of multiple erythematous macules that rapidly evolve to form 3 to 15 mm inflammatory papules and papulovesicles, some of which develop hemorrhagic or necrotic crusts (",
"    <a class=\"graphic graphic_picture graphicRef57911 graphicRef83096 graphicRef85773 \" href=\"UTD.htm?24/26/25002\">",
"     picture 1A-C",
"    </a>",
"    ). Although the trunk, proximal extremities, and skin flexures are the most common sites for involvement, any cutaneous surface may be affected [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17369/abstract/21\">",
"     21",
"    </a>",
"    ]. Mucosal involvement is typically absent.",
"   </p>",
"   <p>",
"    The individual skin lesions of PLEVA usually appear and resolve over the course of a few weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17369/abstract/22\">",
"     22",
"    </a>",
"    ]. However, new lesions often develop as earlier lesions resolve, resulting in ongoing disease and the simultaneous presence of lesions in various stages of development. Hypopigmentation and hyperpigmentation frequently persist after lesion resolution (",
"    <a class=\"graphic graphic_picture graphicRef85773 \" href=\"UTD.htm?0/3/61\">",
"     picture 1C",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17369/abstract/3\">",
"     3",
"    </a>",
"    ]. Scarring may or may not develop.",
"   </p>",
"   <p>",
"    The cutaneous lesions of PLEVA may be asymptomatic, pruritic, or associated with a burning sensation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17369/abstract/21,23\">",
"     21,23",
"    </a>",
"    ]. Systemic symptoms are often absent, but in a minority of patients, fevers or arthralgias occur [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17369/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Occasionally, patients experience infectious symptoms prior to the onset of the skin eruption. In one retrospective series that included 71 children with PLEVA, 46 children with pityriasis lichenoides chronica (PLC), and 7 children with manifestations of both conditions, an infection (most commonly an upper respiratory infection) preceded the onset of skin disease in 28 children (23 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17369/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1433299\">",
"    <span class=\"h2\">",
"     FUMHD",
"    </span>",
"    &nbsp;&mdash;&nbsp;FUMHD may occur de novo or in the setting of preexisting PLEVA [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17369/abstract/4\">",
"     4",
"    </a>",
"    ]. Compared with PLEVA, the clinical manifestations of FUMHD are more severe. Affected patients develop an acute eruption of necrotic papules that rapidly evolve to form necrotic plaques and ulcers that reach up to a few centimeters in diameter (",
"    <a class=\"graphic graphic_picture graphicRef86326 \" href=\"UTD.htm?38/23/39280\">",
"     picture 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17369/abstract/22\">",
"     22",
"    </a>",
"    ]. Hemorrhagic bullae and oral, genital, and conjunctival mucosal ulcerations may also occur [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17369/abstract/1\">",
"     1",
"    </a>",
"    ]. The skin lesions often resolve with atrophic scarring [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17369/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The cutaneous findings of FUMHD are accompanied by persistent high fevers (up to 40&deg;C) and fatigue. Internal involvement is common, and may manifest as cardiomyopathy, central nervous system vasculitis, arthritis, interstitial pneumonitis, hematologic abnormalities, abdominal pain, diarrhea, sepsis, or other disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17369/abstract/5,6,24-27\">",
"     5,6,24-27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1433461\">",
"    <span class=\"h1\">",
"     DISEASE COURSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;PLEVA often follows a relapsing and remitting course prior to spontaneous resolution, and periods of complete or near complete remission may be interspersed with periods of greater disease activity. The duration of PLEVA prior to resolution is highly variable, ranging from a few weeks to years. As an example, a retrospective study that included 71 children with PLEVA found a median duration of PLEVA of 18 months (range 4 to 108 months) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17369/abstract/3\">",
"     3",
"    </a>",
"    ]. In contrast, a retrospective study that included five patients with PLEVA and one patient with FUMHD found an average duration of disease of only 1.6 months [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17369/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    During the course of PLEVA, patients can develop scaly, red-brown papules that are consistent with pityriasis lichenoides chronica (PLC) alongside lesions consistent with PLEVA, and occasionally, patients completely transition from PLEVA to PLC [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17369/abstract/29\">",
"     29",
"    </a>",
"    ]. These observations have been used to support the concept that PLEVA and PLC represent a spectrum of a single disease. (See",
"    <a class=\"local\" href=\"#H8868246\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    FUMHD is a serious and potentially fatal disease. A 2008 review found that 9 of 40 reported cases (15 children and 25 adults) resulted in death [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17369/abstract/4\">",
"     4",
"    </a>",
"    ]. All deaths occurred in adults. FUMHD usually does not recur [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17369/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8868239\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The recognition of consistent cutaneous findings raises suspicion for PLEVA. A skin biopsy is required to confirm the diagnosis and rule out other disorders that can closely resemble PLEVA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H842577\">",
"    <span class=\"h2\">",
"     Biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The key histopathologic findings of PLEVA are found in the epidermis and dermis; thus, the biopsy specimen must adequately sample both of these structures. We typically obtain a tissue specimen via a 4 mm punch biopsy. Alternatively, an incisional biopsy can be performed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/20/40264?source=see_link&amp;anchor=H5#H5\">",
"     \"Skin biopsy techniques\", section on 'Biopsy techniques'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In FUMHD, the recognition of ulceration in the pathology specimen can assist with the interpretation of the biopsy findings. Therefore, in patients with suspected FUMHD, the biopsy specimen should include the edge of an ulcer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H842570\">",
"    <span class=\"h2\">",
"     Histopathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The histologic findings of PLEVA are not pathognomonic, but when reviewed in conjunction with the clinical context, are valuable for diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17369/abstract/3,30\">",
"     3,30",
"    </a>",
"    ]. Typical histopathologic findings in PLEVA include [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17369/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Parakeratosis, spongiosis, mild to moderate epidermal acanthosis",
"     </li>",
"     <li>",
"      Vacuolar alteration of the basal layer",
"     </li>",
"     <li>",
"      Exocytosis of lymphocytes and erythrocytes into the epidermis",
"     </li>",
"     <li>",
"      Moderately dense, wedge-shaped lymphohistiocytic infiltrate extending from the papillary dermis into the deep reticular dermis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional findings that may be present include epidermal erosions or necrosis, vesiculation, endothelial swelling, dermal hemorrhage, and papillary dermal edema. Vasculitis is rare.",
"   </p>",
"   <p>",
"    The histopathologic findings of FUHMD resemble the findings in PLEVA with a few exceptions [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17369/abstract/1\">",
"     1",
"    </a>",
"    ]. The perivascular inflammatory infiltrate tends to be denser and necrosis is more prominent. In addition, leukocytoclastic vasculitis is a prominent feature in FUMHD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1433309\">",
"    <span class=\"h2\">",
"     Immunohistochemistry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunohistochemical studies can aid in confirming the diagnosis of PLEVA. The inflammatory infiltrate is usually primarily composed of CD8+ T lymphocytes. Unlike lymphomatoid papulosis (LyP), CD30 stains are usually negative [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17369/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/23/7546?source=see_link&amp;anchor=H18325888#H18325888\">",
"     \"Lymphomatoid papulosis\", section on 'Differential diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/23/7546?source=see_link\">",
"     \"Lymphomatoid papulosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27786987\">",
"    <span class=\"h2\">",
"     Laboratory studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;No serologic tests are specific for the diagnosis of PLEVA. Leukocytosis and an elevated erythrocyte sedimentation rate or C-reactive protein level are common findings in FUMHD [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17369/abstract/31\">",
"     31",
"    </a>",
"    ]. Depending on the extent and type of internal involvement, patients with FUMHD may exhibit a variety of other laboratory abnormalities. (See",
"    <a class=\"local\" href=\"#H1433299\">",
"     'FUMHD'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Based upon the reports of an association of PLEVA with infection, laboratory studies may be used to evaluate for evidence of existing or preceding infection if the clinical scenario suggests this possibility. Examples of the infections that are most frequently considered include group A",
"    <em>",
"     Streptococcus",
"    </em>",
"    ,",
"    <em>",
"     Toxoplasma gondii",
"    </em>",
"    , human immunodeficiency virus, and Epstein-Barr virus infections [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17369/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8868223\">",
"     'Pathogenesis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8868246\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple inflammatory and infectious disorders share clinical features with PLEVA. Assessment of the clinical history, examination of the morphology and distribution of skin lesions, and review of the pathology findings facilitate the differentiation of PLEVA from these disorders.",
"   </p>",
"   <p>",
"    Examples of disorders in the differential diagnosis of PLEVA are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Lymphomatoid papulosis &ndash;",
"      </strong>",
"      Lymphomatoid papulosis (LyP) is the disease that most closely resembles PLEVA (",
"      <a class=\"graphic graphic_table graphicRef75494 \" href=\"UTD.htm?26/40/27276\">",
"       table 1",
"      </a>",
"      ). Patients present with recurrent crops of inflammatory papules and small nodules that spontaneously regress, usually within several weeks (",
"      <a class=\"graphic graphic_picture graphicRef77791 \" href=\"UTD.htm?41/60/42946\">",
"       picture 4",
"      </a>",
"      ). Similar to PLEVA, crusted, hemorrhagic, and necrotic lesions may be present.",
"      <br/>",
"      <br/>",
"      The histological and immunohistochemical features of LyP differ from PLEVA and are useful for distinguishing between these diseases. LyP is characterized by a dermal infiltrate composed of large atypical lymphocytes that are CD30+ (",
"      <a class=\"graphic graphic_picture graphicRef82763 \" href=\"UTD.htm?36/13/37080\">",
"       picture 5",
"      </a>",
"      ). In contrast, atypical cells and CD30+ cells are few or absent in PLEVA. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/23/7546?source=see_link\">",
"       \"Lymphomatoid papulosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Pityriasis lichenoides chronica &ndash;",
"      </strong>",
"      Pityriasis lichenoides chronica (PLC) is considered to be on a disease spectrum with PLEVA. Unlike PLEVA, which is characterized by the acute eruption of crusting and hemorrhagic papules, the lesions of PLC are usually red-brown papules with overlying micaceous scale that regress over the course of several weeks to months (",
"      <a class=\"graphic graphic_picture graphicRef71210 \" href=\"UTD.htm?18/50/19233\">",
"       picture 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/61/17369/abstract/22\">",
"       22",
"      </a>",
"      ]. Of note, patients with PLEVA may simultaneously develop lesions consistent with PLC and occasionally transition to PLC from PLEVA [",
"      <a class=\"abstract\" href=\"UTD.htm?16/61/17369/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Varicella &ndash;",
"      </strong>",
"      The acute development of papulovesicles on multiple areas of the skin is typical of varicella (",
"      <a class=\"graphic graphic_picture graphicRef55533 \" href=\"UTD.htm?36/3/36927\">",
"       picture 6",
"      </a>",
"      ). The lesions are often described as a dewdrop on a rose petal. Pruritus is usually present. The course of the disease is shorter than PLEVA, usually lasting only one to two weeks. Immunosuppressed patients may develop disseminated varicella, which presents with larger, hemorrhagic skin lesions and a longer disease course. Polymerase chain reaction or direct fluorescent antibody testing can be used to confirm the diagnosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/44/33480?source=see_link\">",
"       \"Clinical features of varicella-zoster virus infection: Chickenpox\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/4/77?source=see_link\">",
"       \"Diagnosis of varicella-zoster virus infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Disseminated herpes simplex virus &ndash;",
"      </strong>",
"      In immunocompromised patients and patients who have a compromised skin barrier (eg, atopic dermatitis, Darier disease), herpes simplex virus infection may result in the development of widespread vesicles, pustules, and crusts (",
"      <a class=\"graphic graphic_picture graphicRef62779 \" href=\"UTD.htm?22/57/23443\">",
"       picture 7",
"      </a>",
"      ). The term &ldquo;eczema herpeticum&rdquo; is used to describe this occurrence in patients with atopic dermatitis. Polymerase chain reaction or direct fluorescent antibody testing can be used to identify herpes simplex infection. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/20/40265?source=see_link&amp;anchor=H5#H5\">",
"       \"Clinical manifestations and diagnosis of herpes simplex virus type 1 infection\", section on 'Immunocompromised hosts'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/20/40265?source=see_link&amp;anchor=H31627071#H31627071\">",
"       \"Clinical manifestations and diagnosis of herpes simplex virus type 1 infection\", section on 'Eczema herpeticum'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Arthropod bites &ndash;",
"      </strong>",
"      Multiple arthropod bites may result in the acute development of widespread, often pruritic, inflammatory papules (",
"      <a class=\"graphic graphic_picture graphicRef78799 \" href=\"UTD.htm?13/63/14321\">",
"       picture 8",
"      </a>",
"      ). Vesiculation and necrosis are infrequent findings. The patient history is useful for diagnosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/35/28216?source=see_link&amp;anchor=H2#H2\">",
"       \"Insect bites\", section on 'Clinical manifestations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Gianotti-Crosti syndrome &ndash;",
"      </strong>",
"      Gianotti-Crosti syndrome is an uncommon disorder that usually occurs in young children. Children often have symptoms of an upper respiratory or gastrointestinal infection prior to the eruption of papules and papulovesicles primarily distributed on the face, buttocks, or extremities (",
"      <a class=\"graphic graphic_picture graphicRef67780 \" href=\"UTD.htm?10/9/10385\">",
"       picture 9",
"      </a>",
"      ). Hemorrhagic lesions may be present. Lymphadenopathy and hepatomegaly may accompany the cutaneous symptoms. The eruption typically resolves spontaneously within weeks to months. The morphology and distribution of lesions and biopsy findings can aid in distinguishing this disorder from PLEVA. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/35/23097?source=see_link\">",
"       \"Gianotti-Crosti syndrome (papular acrodermatitis)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Langerhans cell histiocytosis &ndash;",
"      </strong>",
"      In infants and young children, Langerhans cell histiocytosis (LCH) often presents with hemorrhagic papules (",
"      <a class=\"graphic graphic_picture graphicRef57722 graphicRef69504 \" href=\"UTD.htm?38/9/39064\">",
"       picture 10A-B",
"      </a>",
"      ). Unlike PLEVA, the eruption is primarily localized in seborrheic or intertriginous areas such as inguinal folds, axillae, scalp, and posterior auricular areas. A skin biopsy is useful for diagnosing LCH. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/53/21338?source=see_link&amp;anchor=H452648848#H452648848\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis\", section on 'Skin and oral mucosa'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8868253\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H842676\">",
"    <span class=\"h2\">",
"     Approach to treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because PLEVA is a benign, usually self-limited disorder, clinical follow-up without pharmacologic treatment is an option for the management of children and adults with limited, nonscarring disease who are not bothered by the skin lesions. However, patients with extensive, persistent, symptomatic, scarring, or cosmetically disfiguring disease often desire treatment.",
"   </p>",
"   <p>",
"    Due to the wide variation in the duration of PLEVA prior to spontaneous resolution, randomized trials to evaluate the treatments for PLEVA would be of value for confirming the effectiveness of interventions. However, PLEVA is a rare disorder, and data on the interventions for PLEVA are limited.",
"   </p>",
"   <p>",
"    Antibiotic therapy with tetracyclines or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    and phototherapy are considered first-line treatments based upon retrospective studies and case reports that suggest treatment benefit and the relatively low risk for severe adverse effects associated with these interventions. Both modalities often require two to three months of treatment to achieve satisfactory improvement, which may or may not persist after the discontinuation of therapy.",
"   </p>",
"   <p>",
"    Data are insufficient to determine the comparative efficacy of oral antibiotics and phototherapy for PLEVA, and our decision of which modality to utilize as initial therapy primarily rests upon the consideration of patient characteristics and preferences. Factors such as comorbidities (eg, photosensitive disorders or melanoma), the cost and availability of phototherapy, and the multiple clinical visits required for phototherapy limit the use of phototherapy in some patients.",
"   </p>",
"   <p>",
"    In children, we typically attempt treatment with oral antibiotic therapy prior to phototherapy due to the paucity of data on the long term effects of phototherapy in children. Moreover, some children are unable to fully comply with the safety measures necessary for phototherapy.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     Methotrexate",
"    </a>",
"    is an additional treatment option that has appeared to be beneficial in individual patients with PLEVA. Due to concern regarding the adverse effects of this drug, we typically reserve methotrexate for patients who have failed oral antibiotics and phototherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3589393\">",
"    <span class=\"h2\">",
"     First-line therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;First-line therapies for PLEVA include systemic antibiotics and phototherapy. Topical corticosteroids may be useful for improving symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H842699\">",
"    <span class=\"h3\">",
"     Systemic antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibiotics with antiinflammatory properties are the primary antibiotics utilized for PLEVA. Adolescents and adults are usually treated with tetracyclines. Tetracyclines are contraindicated in children under the age of nine due to deleterious effects on tooth development. Thus,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    is typically utilized for antibiotic treatment in children.",
"   </p>",
"   <p>",
"    Our typical treatment regimen for adults is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"       Tetracycline",
"      </a>",
"      2000 mg per day",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       Doxycycline",
"      </a>",
"      100 to 200 mg per day",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"       Minocycline",
"      </a>",
"      100 to 200 mg per day",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Our typical treatment regimen for children is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"       Erythromycin",
"      </a>",
"      30 to 50",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We continue these doses until complete or almost complete lesion resolution is attained (typically within one to three months), then taper over one to two months as tolerated. Patients who relapse upon tapering or drug discontinuation can be given longer courses of therapy. If no response is evident after three months of treatment with an antibiotic, we discontinue treatment and consider phototherapy.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     Azithromycin",
"    </a>",
"    is an additional therapeutic option for children and adults, but experience with this drug in PLEVA is more limited. Data on the efficacy of specific antibiotics are provided below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H572995\">",
"    <span class=\"h4\">",
"     Tetracyclines",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of tetracyclines in PLEVA is based upon an uncontrolled study that demonstrated efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    in pityriasis lichenoides and case reports. In the uncontrolled study, 12 of 13 patients with pityriasis lichenoides who were treated with tetracycline (2 g per day until lesions subsided followed by 1 g per day for one month) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17369/abstract/32\">",
"     32",
"    </a>",
"    ] had great improvement within four weeks. The proportion of responders who had PLEVA or PLC was not specified. However, the patient who failed to respond to treatment had features of PLEVA. Seven of the responders required the continuation of tetracycline (1 g per day) to maintain improvement.",
"   </p>",
"   <p>",
"    Improvement following treatment with tetracyclines has been documented in individual reports of patients with PLEVA. Complete suppression of skin lesions occurred within three weeks in an adolescent girl treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    (2 g per day) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17369/abstract/33\">",
"     33",
"    </a>",
"    ], and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"     minocycline",
"    </a>",
"    (100 mg per day) was associated with improvement in at least one of two patients with PLEVA in a retrospective series [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17369/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H573002\">",
"    <span class=\"h4\">",
"     Erythromycin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Support for the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    in PLEVA is derived from several retrospective studies, most of which combine patients with PLEVA and PLC [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17369/abstract/3,28,34,35\">",
"     3,28,34,35",
"    </a>",
"    ]. Examples of studies in which the majority of patients had PLEVA include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a retrospective study that included 71 children with PLEVA, 46 children with PLC, and 7 children with a mixed presentation, 80 percent were treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"       erythromycin",
"      </a>",
"      (30 to 50",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/61/17369/abstract/3\">",
"       3",
"      </a>",
"      ]. Among the 57 patients who were available for follow-up after treatment with erythromycin, 34 (67 percent) improved within a median of two months. Sixty-one percent of the responders achieved complete clearance of active skin lesions. The maintenance of the response after treatment cessation was not assessed.",
"     </li>",
"     <li>",
"      In a retrospective study of 14 children with PLEVA and 8 children with PLC, 11 of 19 patients who were available for follow-up achieved remission (usually within two months). Seven children were able to discontinue",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"       erythromycin",
"      </a>",
"      after two to five months of treatment and remained free of lesions for follow-up periods that ranged from six weeks to three years [",
"      <a class=\"abstract\" href=\"UTD.htm?16/61/17369/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Less favorable results with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    have been reported. In a case series in which eight children with PLEVA were treated with erythromycin for at least six weeks, two improved, four had no change in disease severity, and two worsened during treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17369/abstract/36\">",
"     36",
"    </a>",
"    ]. In addition, in a retrospective study in which eight children with pityriasis lichenoides (subtype unspecified) were treated with oral erythromycin, only two children had disease clearance after three months of treatment, one of whom relapsed within four weeks after treatment cessation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17369/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H573011\">",
"    <span class=\"h4\">",
"     Azithromycin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     Azithromycin",
"    </a>",
"    (500 mg for one day followed by 250 mg for four days taken on the first and third weeks of the month) was effective within one month for an adult woman with PLEVA who failed to respond to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    and within two months in a child with PLEVA who did not improve with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17369/abstract/37\">",
"     37",
"    </a>",
"    ]. A child treated with a combination of azithromycin and topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    also seemed to benefit from treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17369/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The potential adverse effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/30/1514?source=see_link&amp;anchor=H19#H19\">",
"     \"Azithromycin, clarithromycin, and telithromycin\", section on 'Adverse reactions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H842706\">",
"    <span class=\"h3\">",
"     Phototherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Phototherapy with ultraviolet (UV) light is frequently utilized for the treatment of pityriasis lichenoides and appears to be effective in many patients with PLEVA [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17369/abstract/1,39\">",
"     1,39",
"    </a>",
"    ]. The modalities utilized include narrowband UVB, broadband UVB, psoralen plus UVA (PUVA), and UVA1.",
"   </p>",
"   <p>",
"    As noted above, comorbidities and the availability, feasibility, and cost of phototherapy are limiting factors for some patients. Phototherapy is usually administered at least three times weekly at the start of therapy and tapered after a satisfactory response. At least two to three months of treatment is usually required to achieve improvement. Similar to antibiotic therapy, relapses occur with variable frequency after the discontinuation of treatment.",
"   </p>",
"   <p>",
"    The types of phototherapy that have been utilized in PLEVA are reviewed below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       UVB &ndash;",
"      </strong>",
"      UVB is our first choice for phototherapy. The use of UVB phototherapy in pityriasis lichenoides is supported by retrospective studies and case series [",
"      <a class=\"abstract\" href=\"UTD.htm?16/61/17369/abstract/39\">",
"       39",
"      </a>",
"      ]. In a retrospective study that included 23 patients with PLEVA (all with skin phototypes I to III (",
"      <a class=\"graphic graphic_table graphicRef60541 \" href=\"UTD.htm?15/37/15963\">",
"       table 2",
"      </a>",
"      )) who were treated with narrowband UVB, 15 (65 percent) achieved at least 90 percent clearance of disease (mean number of treatments = 43, mean cumulative dose = 23",
"      <span class=\"nowrap\">",
"       J/cm",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?16/61/17369/abstract/39\">",
"       39",
"      </a>",
"      ]. The remaining eight patients achieved partial responses (at least 50 to 90 percent clearance). Two of the complete responders relapsed within one year.",
"      <br/>",
"      <br/>",
"      Either narrowband UVB or broadband UVB may be used for the treatment of PLEVA. A retrospective study of 29 patients with PLC, PLEVA, or an overlap syndrome did not find a significant difference in response rates to these modalities (93 percent in each treatment group responded) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/61/17369/abstract/40\">",
"       40",
"      </a>",
"      ]. Additional studies are necessary to confirm whether differences in efficacy exist.",
"     </li>",
"     <li>",
"      <strong>",
"       PUVA",
"      </strong>",
"      &ndash; Complete responses to PUVA have been documented in multiple case reports, some of which demonstrated long-term clearance, and others in which recurrences appeared after treatment cessation [",
"      <a class=\"abstract\" href=\"UTD.htm?16/61/17369/abstract/1\">",
"       1",
"      </a>",
"      ]. However, in the absence of data that indicate superior efficacy of PUVA over UVB phototherapy, the need for the administration of a systemic photosensitizer and the potential for additional adverse effects related to the photosensitizing agent make PUVA a less favorable first-line option for phototherapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/24/33160?source=see_link&amp;anchor=H31513912#H31513912\">",
"       \"Psoralen plus ultraviolet A (PUVA) photochemotherapy\", section on 'Safety measures'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/24/33160?source=see_link&amp;anchor=H31513947#H31513947\">",
"       \"Psoralen plus ultraviolet A (PUVA) photochemotherapy\", section on 'Adverse effects'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       UVA1",
"      </strong>",
"      &ndash; Data on the efficacy of UVA1 phototherapy are more limited than for UVB phototherapy. UVA1 phototherapy has been associated with complete responses in a few patients with PLEVA [",
"      <a class=\"abstract\" href=\"UTD.htm?16/61/17369/abstract/41\">",
"       41",
"      </a>",
"      ]. The availability of UVA1 is primarily restricted to academic centers, limiting the use of this therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Continuing treatment at a reduced frequency (eg, tapering to once every two weeks) after a complete response is attained has been utilized by some clinicians, including ourselves, in an attempt to reduce the likelihood of recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17369/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. The value of maintenance regimens has not been formally studied.",
"   </p>",
"   <p>",
"    Outdoor sun exposure is sometimes tried for patients in whom phototherapy is not feasible. Patients are often instructed to expose the affected areas to midday sunlight for 10 to 20 minutes and to then slowly increase the duration of daily sun exposure to maintain tanned but not burned skin. The duration of sun exposure required is dependent on skin type (",
"    <a class=\"graphic graphic_table graphicRef60541 \" href=\"UTD.htm?15/37/15963\">",
"     table 2",
"    </a>",
"    ). Patients with very fair skin who are unable to tan are not favorable candidates for this therapy.",
"   </p>",
"   <p>",
"    The efficacy of outdoor sun exposure on PLEVA has not been formally evaluated. Our experience suggests that some patients achieve modest benefits. In temperate climates, this option is limited to the time period between late spring and early autumn.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2441257\">",
"    <span class=\"h3\">",
"     Topical agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical corticosteroids may be useful for attaining symptomatic relief or accelerating the resolution of individual lesions; however, these agents are not thought to alter the course of PLEVA. Medium or high potency topical corticosteroids are usually applied to individual lesions once or twice daily for two to three weeks (",
"    <a class=\"graphic graphic_table graphicRef62402 \" href=\"UTD.htm?38/56/39809\">",
"     table 3",
"    </a>",
"    ). In a retrospective study, approximately half of 18 adults and 16 children treated with topical corticosteroids found these agents useful for alleviating disease signs and symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17369/abstract/23\">",
"     23",
"    </a>",
"    ]. Case supports suggest that topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    ointment may also be useful for PLEVA [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17369/abstract/38,42\">",
"     38,42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H842714\">",
"    <span class=\"h2\">",
"     Refractory disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Case reports indicate that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    may be effective for PLEVA [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17369/abstract/36,43-45\">",
"     36,43-45",
"    </a>",
"    ]. Methotrexate is administered once weekly at doses between 7.5 to 20 mg per week. In some patients, improvement has been noted within a few weeks.",
"   </p>",
"   <p>",
"    Due to the potential for serious adverse effects related to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    therapy, we typically reserve this treatment for patients who fail to respond to first-line therapies. Relapses during or after tapering of methotrexate appear to be common [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17369/abstract/43-45\">",
"     43-45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other therapies that have been suggested for refractory disease include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/1/39958?source=see_link\">",
"     acitretin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17369/abstract/1\">",
"     1",
"    </a>",
"    ]. Combination therapy with acitretin and PUVA was dramatically effective in two patients with refractory PLEVA within a few weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17369/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H842729\">",
"    <span class=\"h2\">",
"     Febrile ulceronecrotic Mucha-Habermann disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Due to the rarity of FUMHD and the multiple therapies often administered simultaneously to these patients, the best approach to the treatment of FUMHD is unknown. Case reports document the use of a wide variety of therapeutic agents.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     Methotrexate",
"    </a>",
"    appears to be the most consistently beneficial therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17369/abstract/4\">",
"     4",
"    </a>",
"    ]. Systemic glucocorticoids have been utilized in many reported cases, but whether they are truly beneficial remains unclear. Other agents that have been utilized for FUMHD include intravenous immunoglobulin, antibiotics,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , and phototherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17369/abstract/27\">",
"     27",
"    </a>",
"    ]. Inpatient management is usually required for these systemically ill patients.",
"   </p>",
"   <p>",
"    Although elevated TNF-alpha levels were detected in a child with FUMHD, a role for TNF-alpha inhibitors in FUMHD remains to be determined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8868283\">",
"    <span class=\"h1\">",
"     ASSOCIATION WITH LYMPHOMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rare reports of the development of cutaneous T cell lymphoma in patients with a history of PLEVA exist. Two children in whom this was thought to have occurred have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17369/abstract/47\">",
"     47",
"    </a>",
"    ]. PLC has also been infrequently linked to cutaneous lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17369/abstract/48,49\">",
"     48,49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In light of the rarity of such reports, PLEVA is generally accepted as a disease with a benign clinical course. Signs that may suggest cutaneous lymphoma include the development of persistent cutaneous inflammatory patches or plaques or tumor-like nodules.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8868290\">",
"    <span class=\"h1\">",
"     PATIENT FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should be followed periodically (every three to six months) if treatment is deferred. This allows the clinician to discuss treatment if the disorder persists and provides the opportunity for reevaluation if the clinical findings evolve in a manner that suggests another diagnosis. We typically follow treated patients closely to monitor the effect of therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2441862\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      PLEVA is an uncommon cutaneous disorder that is characterized by the acute development of inflammatory papules with hemorrhagic or necrotic crusts on the skin (",
"      <a class=\"graphic graphic_picture graphicRef57911 graphicRef83096 graphicRef85773 \" href=\"UTD.htm?24/26/25002\">",
"       picture 1A-C",
"      </a>",
"      ). PLEVA may occur at any age, but children and young adults are most frequently affected. (See",
"      <a class=\"local\" href=\"#H8868216\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The pathogenesis of PLEVA is not well understood. Theories on the pathogenesis of PLEVA include a view of PLEVA as a benign lymphoproliferative disorder or as a hypersensitivity response to infection. (See",
"      <a class=\"local\" href=\"#H8868223\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The cutaneous lesions of PLEVA tend to primarily appear on the trunk, proximal extremities, and skin flexures. Although individual lesions often resolve within a few weeks, new crops of lesions often develop resulting in lesions at different stages of development. (See",
"      <a class=\"local\" href=\"#H8868230\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      PLEVA is a benign, self-limited disorder. However, symptoms may persist for weeks, months, or years. (See",
"      <a class=\"local\" href=\"#H1433461\">",
"       'Disease course'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Febrile ulceronecrotic Mucha-Habermann disease (FUMHD) is a rare, severe variant of PLEVA characterized by systemic illness, fever, and large ulcerated skin lesions. FUMHD can be fatal, particularly in adults. (See",
"      <a class=\"local\" href=\"#H1433299\">",
"       'FUMHD'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1433461\">",
"       'Disease course'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of PLEVA is made through the assessment of clinical and histopathological findings. The disorder that bears the closest clinical resemblance to PLEVA is lymphomatoid papulosis. A skin biopsy and immunohistochemical studies are useful for distinguishing between these diseases. (See",
"      <a class=\"local\" href=\"#H8868239\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8868246\">",
"       'Differential diagnosis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/23/7546?source=see_link\">",
"       \"Lymphomatoid papulosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Data are limited on the treatment options for PLEVA. Since the disease may be asymptomatic and self-limited, treatment is not always required. For adult patients who desire treatment, we suggest treatment with oral tetracyclines or UVB phototherapy, based upon patient preferences and treatment availability (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For children with PLEVA we suggest treatment with oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"       erythromycin",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Children who fail to improve with oral erythromycin are candidates for UVB phototherapy. (See",
"      <a class=\"local\" href=\"#H8868253\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       Methotrexate",
"      </a>",
"      is a treatment option for PLEVA that is refractory to oral antibiotics and phototherapy. The risks and benefits of treatment with this agent should be considered carefully. (See",
"      <a class=\"local\" href=\"#H842714\">",
"       'Refractory disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The best approach to treatment of FUMHD has not been established.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       Methotrexate",
"      </a>",
"      and other systemic immunomodulators may be beneficial. Further study is necessary to determine the appropriate approach to the treatment of this disease. (See",
"      <a class=\"local\" href=\"#H842729\">",
"       'Febrile ulceronecrotic Mucha-Habermann disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17369/abstract/1\">",
"      Bowers S, Warshaw EM. Pityriasis lichenoides and its subtypes. J Am Acad Dermatol 2006; 55:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17369/abstract/2\">",
"      Hoshina D, Akiyama M, Hamasaka K, Shimizu H. An infantile case of pityriasis lichenoides et varioliformis acuta. Br J Dermatol 2007; 157:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17369/abstract/3\">",
"      Ersoy-Evans S, Greco MF, Mancini AJ, et al. Pityriasis lichenoides in childhood: a retrospective review of 124 patients. J Am Acad Dermatol 2007; 56:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17369/abstract/4\">",
"      Sotiriou E, Patsatsi A, Tsorova C, et al. Febrile ulceronecrotic Mucha-Habermann disease: a case report and review of the literature. Acta Derm Venereol 2008; 88:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17369/abstract/5\">",
"      Tsianakas A, Hoeger PH. Transition of pityriasis lichenoides et varioliformis acuta to febrile ulceronecrotic Mucha-Habermann disease is associated with elevated serum tumour necrosis factor-alpha. Br J Dermatol 2005; 152:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17369/abstract/6\">",
"      Cozzio A, Hafner J, Kempf W, et al. Febrile ulceronecrotic Mucha-Habermann disease with clonality: a cutaneous T-cell lymphoma entity? J Am Acad Dermatol 2004; 51:1014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17369/abstract/7\">",
"      Dereure O, Levi E, Kadin ME. T-Cell clonality in pityriasis lichenoides et varioliformis acuta: a heteroduplex analysis of 20 cases. Arch Dermatol 2000; 136:1483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17369/abstract/8\">",
"      Weiss LM, Wood GS, Ellisen LW, et al. Clonal T-cell populations in pityriasis lichenoides et varioliformis acuta (Mucha-Habermann disease). Am J Pathol 1987; 126:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17369/abstract/9\">",
"      Rongioletti F, Rivara G, Rebora A. Pityriasis lichenoides et varioliformis acuta and acquired toxoplasmosis. Dermatologica 1987; 175:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17369/abstract/10\">",
"      Boss JM, Boxley JD, Summerly R, Sutton RN. The detection of Epstein Barr virus antibody in 'exanthematic' dermatoses with special reference to pityriasis lichenoides. A preliminary survey. Clin Exp Dermatol 1978; 3:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17369/abstract/11\">",
"      Tomasini D, Tomasini CF, Cerri A, et al. Pityriasis lichenoides: a cytotoxic T-cell-mediated skin disorder. Evidence of human parvovirus B19 DNA in nine cases. J Cutan Pathol 2004; 31:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17369/abstract/12\">",
"      English JC 3rd, Collins M, Bryant-Bruce C. Pityriasis lichenoides et varioliformis acuta and group-A beta hemolytic streptococcal infection. Int J Dermatol 1995; 34:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17369/abstract/13\">",
"      Ostlere LS, Langtry JA, Branfoot AC, Staughton RC. HIV seropositivity in association with pityriasis lichenoides et varioliformis acuta. Clin Exp Dermatol 1992; 17:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17369/abstract/14\">",
"      Smith JJ, Oliver GF. Febrile ulceronecrotic Mucha-Habermann disease associated with herpes simplex virus type 2. J Am Acad Dermatol 2009; 60:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17369/abstract/15\">",
"      Longley J, Demar L, Feinstein RP, et al. Clinical and histologic features of pityriasis lichenoides et varioliformis acuta in children. Arch Dermatol 1987; 123:1335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17369/abstract/16\">",
"      Herron MD, Bohnsack JF, Vanderhooft SL. Septic, CD-30 positive febrile ulceronecrotic pityriasis lichenoides et varioliformis acuta. Pediatr Dermatol 2005; 22:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17369/abstract/17\">",
"      Kawamura K, Tsuji T, Kuwabara Y. Mucha-Habermann disease-like eruptions due to Tegafur. J Dermatol 1999; 26:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17369/abstract/18\">",
"      Stosiek N, Peters KP, von den Driesch P. [Pityriasis-lichenoides-et-varioliformis-acuta-like drug exanthema caused by astemizole]. Hautarzt 1993; 44:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17369/abstract/19\">",
"      Jowkar F, Namazi MR, Bahmani M, Monabati A. Triggering of pityriasis lichenoides et varioliformis acuta by radiocontrast iodide. J Dermatolog Treat 2008; 19:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17369/abstract/20\">",
"      Hollander A, Grots IA. Mucha-Habermann disease following estrogen-progesterone therapy. Arch Dermatol 1973; 107:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17369/abstract/21\">",
"      Khachemoune A, Blyumin ML. Pityriasis lichenoides: pathophysiology, classification, and treatment. Am J Clin Dermatol 2007; 8:29.",
"     </a>",
"    </li>",
"    <li>",
"     Wood GS, Hu CH, Liu R. Parapsoriasis and pityriasis lichenoides. In: Fitzpatrick's Dermatology in General Medicine, 8th ed, Goldsmith LA, Katz SI, Gilchrest BA, et al..  (Eds), McGraw Hill, 2012. Vol 1, p.285.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17369/abstract/23\">",
"      Wahie S, Hiscutt E, Natarajan S, Taylor A. Pityriasis lichenoides: the differences between children and adults. Br J Dermatol 2007; 157:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17369/abstract/24\">",
"      Rosman IS, Liang LC, Patil S, et al. Febrile ulceronecrotic Mucha-Habermann disease with central nervous system vasculitis. Pediatr Dermatol 2013; 30:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17369/abstract/25\">",
"      Auster BI, Santa Cruz DJ, Eisen AZ. Febrile ulceronecrotic Mucha-Habermann's disease with interstitial pneumonitis. J Cutan Pathol 1979; 6:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17369/abstract/26\">",
"      Luberti AA, Rabinowitz LG, Ververeli KO. Severe febrile Mucha-Habermann's disease in children: case report and review of the literature. Pediatr Dermatol 1991; 8:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17369/abstract/27\">",
"      Perrin BS, Yan AC, Treat JR. Febrile ulceronecrotic Mucha-Habermann disease in a 34-month-old boy: a case report and review of the literature. Pediatr Dermatol 2012; 29:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17369/abstract/28\">",
"      Roman&iacute; J, Puig L, Fern&aacute;ndez-Figueras MT, de Moragas JM. Pityriasis lichenoides in children: clinicopathologic review of 22 patients. Pediatr Dermatol 1998; 15:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17369/abstract/29\">",
"      Fernandes NF, Rozdeba PJ, Schwartz RA, et al. Pityriasis lichenoides et varioliformis acuta: a disease spectrum. Int J Dermatol 2010; 49:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17369/abstract/30\">",
"      Hood AF, Mark EJ. Histopathologic diagnosis of pityriasis lichenoides et varioliformis acuta and its clinical correlation. Arch Dermatol 1982; 118:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17369/abstract/31\">",
"      Ito N, Ohshima A, Hashizume H, et al. Febrile ulceronecrotic Mucha-Habermann's disease managed with methylprednisolone semipulse and subsequent methotrexate therapies. J Am Acad Dermatol 2003; 49:1142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17369/abstract/32\">",
"      Piamphongsant T. Tetracycline for the treatment of pityriasis lichenoides. Br J Dermatol 1974; 91:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17369/abstract/33\">",
"      Shelley WB, Griffith RF. Pityriasis lichennoides et varioliformis acuta. A report of a case controlled by a high dose of tetracycline. Arch Dermatol 1969; 100:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17369/abstract/34\">",
"      Truhan AP, Hebert AA, Esterly NB. Pityriasis lichenoides in children: therapeutic response to erythromycin. J Am Acad Dermatol 1986; 15:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17369/abstract/35\">",
"      Hapa A, Ersoy-Evans S, Karaduman A. Childhood pityriasis lichenoides and oral erythromycin. Pediatr Dermatol 2012; 29:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17369/abstract/36\">",
"      Rasmussen JE. Mucha-Habermann's disease. Arch Dermatol 1979; 115:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17369/abstract/37\">",
"      Skinner RB, Levy AL. Rapid resolution of pityriasis lichenoides et varioliformis acuta with azithromycin. J Am Acad Dermatol 2008; 58:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17369/abstract/38\">",
"      Di Costanzo L, Balato N, La Bella S, Balato A. Successful association in the treatment of pityriasis lichenoides et varioliformis acuta. J Eur Acad Dermatol Venereol 2009; 23:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17369/abstract/39\">",
"      Aydogan K, Saricaoglu H, Turan H. Narrowband UVB (311 nm, TL01) phototherapy for pityriasis lichenoides. Photodermatol Photoimmunol Photomed 2008; 24:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17369/abstract/40\">",
"      Pavlotsky F, Baum S, Barzilai A, et al. UVB therapy of pityriasis lichenoides--our experience with 29 patients. J Eur Acad Dermatol Venereol 2006; 20:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17369/abstract/41\">",
"      Pinton PC, Capezzera R, Zane C, De Panfilis G. Medium-dose ultraviolet A1 therapy for pityriasis lichenoides et varioliformis acuta and pityriasis lichenoides chronica. J Am Acad Dermatol 2002; 47:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17369/abstract/42\">",
"      Simon D, Boudny C, Nievergelt H, et al. Successful treatment of pityriasis lichenoides with topical tacrolimus. Br J Dermatol 2004; 150:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17369/abstract/43\">",
"      Lynch PJ, Saied NK. Methotrexate treatment of pityriasis lichenoides and lymphomatoid papulosis. Cutis 1979; 23:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17369/abstract/44\">",
"      Cornelison RL Jr, Knox JM, Everett MA. Methotrexate for the treatment of Mucha-Habermann disease. Arch Dermatol 1972; 106:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17369/abstract/45\">",
"      Lazaridou E, Fotiadou C, Tsorova C, et al. Resistant pityriasis lichenoides et varioliformis acuta in a 3-year-old boy: successful treatment with methotrexate. Int J Dermatol 2010; 49:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17369/abstract/46\">",
"      Pans&eacute; I, Bourrat E, Rybojad M, Morel P. [Photochemotherapy for pityriasis lichenoides: 3 cases]. Ann Dermatol Venereol 2004; 131:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17369/abstract/47\">",
"      Fortson JS, Schroeter AL, Esterly NB. Cutaneous T-cell lymphoma (parapsoriasis en plaque). An association with pityriasis lichenoides et varioliformis acuta in young children. Arch Dermatol 1990; 126:1449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17369/abstract/48\">",
"      Thomson KF, Whittaker SJ, Russell-Jones R, Charles-Holmes R. Childhood cutaneous T-cell lymphoma in association with pityriasis lichenoides chronica. Br J Dermatol 1999; 141:1146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17369/abstract/49\">",
"      Panizzon RG, Speich R, Dazzi H. Atypical manifestations of pityriasis lichenoides chronica: development into paraneoplasia and non-Hodgkin lymphomas of the skin. Dermatology 1992; 184:65.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15282 Version 1.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-61.234.146.186-043A92644E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_61_17369=[""].join("\n");
var outline_f16_61_17369=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2441862\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8868209\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8868216\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8868223\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8868230\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1433285\">",
"      PLEVA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1433299\">",
"      FUMHD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1433461\">",
"      DISEASE COURSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8868239\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H842577\">",
"      Biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H842570\">",
"      Histopathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1433309\">",
"      Immunohistochemistry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27786987\">",
"      Laboratory studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8868246\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8868253\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H842676\">",
"      Approach to treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3589393\">",
"      First-line therapies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H842699\">",
"      - Systemic antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H572995\">",
"      Tetracyclines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H573002\">",
"      Erythromycin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H573011\">",
"      Azithromycin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H842706\">",
"      - Phototherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2441257\">",
"      - Topical agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H842714\">",
"      Refractory disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H842729\">",
"      Febrile ulceronecrotic Mucha-Habermann disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8868283\">",
"      ASSOCIATION WITH LYMPHOMA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8868290\">",
"      PATIENT FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2441862\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/15282\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/15282|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/29/9685\" title=\"picture 1A\">",
"      Pityriasis lichenoides et varioliformis acuta",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/60/40897\" title=\"picture 1B\">",
"      PLEVA 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/3/61\" title=\"picture 1C\">",
"      Pityriasis lichenoides et varioliformis acuta on thigh",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/50/19233\" title=\"picture 2\">",
"      Pityriasis lichenoides chronica",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/23/39280\" title=\"picture 3\">",
"      Febrile ulceronecrotic Mucha-Habermann disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/60/42946\" title=\"picture 4\">",
"      Lymphomatoid papulosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/13/37080\" title=\"picture 5\">",
"      Lymphomatoid papulosis histology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/3/36927\" title=\"picture 6\">",
"      Rash of primary varicella",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/57/23443\" title=\"picture 7\">",
"      Eczema herpeticum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/63/14321\" title=\"picture 8\">",
"      Flea bites ankle",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/9/10385\" title=\"picture 9\">",
"      Gianotti Crosti",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/62/34786\" title=\"picture 10A\">",
"      Langerhans histiocytosis skin 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/56/4997\" title=\"picture 10B\">",
"      Langerhans histiocytosis skin 2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/15282|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/40/27276\" title=\"table 1\">",
"      Lymphomatoid papulosis differential",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/37/15963\" title=\"table 2\">",
"      Fitzpatrick skin phototypes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/56/39809\" title=\"table 3\">",
"      Topical corticosteroids",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/30/1514?source=related_link\">",
"      Azithromycin, clarithromycin, and telithromycin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/44/33480?source=related_link\">",
"      Clinical features of varicella-zoster virus infection: Chickenpox",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/20/40265?source=related_link\">",
"      Clinical manifestations and diagnosis of herpes simplex virus type 1 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/53/21338?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/4/77?source=related_link\">",
"      Diagnosis of varicella-zoster virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/35/23097?source=related_link\">",
"      Gianotti-Crosti syndrome (papular acrodermatitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/35/28216?source=related_link\">",
"      Insect bites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/23/7546?source=related_link\">",
"      Lymphomatoid papulosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/24/33160?source=related_link\">",
"      Psoralen plus ultraviolet A (PUVA) photochemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/20/40264?source=related_link\">",
"      Skin biopsy techniques",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_61_17370="Epidemiology, clinical manifestations, and diagnosis of the Wolff-Parkinson-White syndrome";
var content_f16_61_17370=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology, clinical manifestations, and diagnosis of the Wolff-Parkinson-White syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/61/17370/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/61/17370/contributors\">",
"     Luigi Di Biase, MD, PhD, FHRS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/61/17370/contributors\">",
"     Edward P Walsh, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/61/17370/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/61/17370/contributors\">",
"     Samuel L&eacute;vy, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/61/17370/contributors\">",
"     Bradley P Knight, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/61/17370/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/61/17370/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/61/17370/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 11, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 1930, Louis Wolff, Sir John Parkinson, and Paul Dudley White published a seminal article describing 11 patients who suffered from attacks of tachycardia associated with a sinus rhythm electrocardiographic (ECG) pattern of bundle branch block with a short PR interval [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17370/abstract/1\">",
"     1",
"    </a>",
"    ]. This was subsequently termed the Wolff-Parkinson-White (WPW) syndrome, although earlier isolated case reports describing similar patients had been published. In 1943, the ECG features of preexcitation were correlated with anatomic evidence for the existence of anomalous bundles of conducting tissue that bypassed all or part of the normal atrioventricular (AV) conduction system (",
"    <a class=\"graphic graphic_figure graphicRef69078 \" href=\"UTD.htm?23/5/23634\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    This topic will review the definition and prevalence of the WPW syndrome. The treatment options for patients with tachyarrhythmias and the WPW syndrome are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/60/15305?source=see_link\">",
"     \"Pharmacologic therapy of arrhythmias associated with the Wolff-Parkinson-White syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8470587\">",
"    <span class=\"h2\">",
"     Normal AV conduction versus accessory AV pathway conduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the normal heart, the atria and the ventricles are electrically isolated, with conduction of electrical impulses from the atria to the ventricles normally occurring via the atrioventricular node (AV) and the His-Purkinje system. Patients with a preexcitation syndrome have an additional pathway, known as an accessory pathway (AP), which directly connects the atria and ventricles, thereby allowing electrical activity to bypass the AV node (",
"    <a class=\"graphic graphic_table graphicRef53343 \" href=\"UTD.htm?26/0/26635\">",
"     table 1",
"    </a>",
"    ). Tissue in the accessory pathways, which are congenital in origin and result from failure of resorption of the myocardial syncytium at the annulus fibrosis of the atrioventricular valves during fetal development, typically conducts electrical impulses more quickly than the AV node, resulting in the shorter PR interval seen on the surface ECG. (See",
"    <a class=\"local\" href=\"#H13260510\">",
"     'Electrocardiographic (ECG) findings'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/0/11272?source=see_link\">",
"     \"Lown-Ganong-Levine syndrome and enhanced atrioventricular nodal conduction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/33/17943?source=see_link\">",
"     \"Mahaim fiber tachycardias\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It has been estimated that most accessory pathways (60 to 75 percent) are capable of bidirectional conduction (anterograde and retrograde) between the atrium and ventricle. However, some accessory pathways (17 to 37 percent) are only capable of conduction in a retrograde fashion from ventricle to atrium [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17370/abstract/2\">",
"     2",
"    </a>",
"    ]. When accessory pathways conduct exclusively in the retrograde direction (so-called \"concealed\" accessory pathways), they do not generate a delta wave and the WPW pattern on the surface ECG but are still capable of supporting reentrant tachycardia. Retrograde conduction can occur following ventricular pacing or premature beats, and it can form the retrograde arm of an orthodromic atrioventricular reentrant tachycardia (AVRT) circuit. The vast majority of concealed accessory pathways are left-sided [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17370/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H13260635\">",
"     'Anatomy'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24311?source=see_link&amp;anchor=H3#H3\">",
"     \"Atrioventricular reentrant tachycardia (AVRT) associated with an accessory pathway\", section on 'Orthodromic AVRT'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Less commonly (5 to 27 percent), an accessory pathway is only capable of conduction in the anterograde direction; in such cases, it can form the antegrade arm of an antidromic atrioventricular reentrant tachycardia (AVRT) circuit. The mechanism responsible for unidirectional conduction along an accessory pathway (anterograde only or retrograde only) remains undetermined. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24311?source=see_link&amp;anchor=H4#H4\">",
"     \"Atrioventricular reentrant tachycardia (AVRT) associated with an accessory pathway\", section on 'Antidromic AVRT'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In some patients, accessory pathways that appear to be concealed may be capable of antegrade conduction in some situations.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If AV nodal conduction is enhanced",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      the AP is left lateral (ie, far from the sinus node), conduction may proceed over the normal AV node-His Purkinje system more quickly than over the AP. In these cases, antegrade AP conduction occurs, but is not manifest on the surface ECG. Transient blockade of AV nodal conduction with adenosine may expose the \"concealed\" pathway.",
"     </li>",
"     <li>",
"      In some patients with left free wall accessory pathways, pacing the left atrium via the coronary sinus, in an area closer to the AP, may be necessary to bring out antegrade AP conduction and overt preexcitation.",
"     </li>",
"     <li>",
"      Some accessory pathways (in any location) may have limited anterograde conduction potential due to a long refractory period and only become manifest at slower heart rates.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13260536\">",
"    <span class=\"h2\">",
"     WPW pattern versus WPW syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two terms, distinguished by the presence or absence of arrhythmias, have been used to describe patients with accessory pathways (AP):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The Wolff-Parkinson-White (WPW) pattern is applied to the patient with preexcitation manifest on an ECG in the absence of symptomatic arrhythmias.",
"     </li>",
"     <li>",
"      The Wolff-Parkinson-White (WPW) syndrome is applied to the patient with both preexcitation manifest on an ECG and symptomatic arrhythmias involving the accessory pathway.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Persons with either the WPW pattern or WPW syndrome can have identical findings on surface ECG. In either situation, anterograde conduction through the accessory pathway results in earlier activation, or preexcitation, of part of the ventricles. The classic electrocardiographic pattern in the WPW pattern and syndrome (",
"    <a class=\"graphic graphic_waveform graphicRef75578 \" href=\"UTD.htm?34/55/35706\">",
"     waveform 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_waveform graphicRef76226 \" href=\"UTD.htm?35/41/36506\">",
"     waveform 2",
"    </a>",
"    ) has two major features: a shortened PR interval and a widened QRS complex due to a delta wave. The ECG findings are discussed in greater detail. (See",
"    <a class=\"local\" href=\"#H13260510\">",
"     'Electrocardiographic (ECG) findings'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Multiple accessory pathways are present in as many as 13 percent of patients referred to an electrophysiologist because of the WPW syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17370/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. The probability is increased in subjects with a family history of preexcitation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17370/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Familial WPW'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13260635\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8470594\">",
"    <span class=\"h2\">",
"     Accessory pathway location",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electrophysiologic studies and mapping have shown that accessory atrioventricular pathways may be located anywhere along the AV ring (groove) or in the septum. The most frequent locations are left lateral (50 percent), posteroseptal (30 percent), right anteroseptal (10 percent), and right lateral (10 percent). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/21/39256?source=see_link\">",
"     \"Anatomy, pathophysiology and localization of accessory pathways in the preexcitation syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Many studies have attempted to correlate the site of the accessory pathway with the ECG pattern [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17370/abstract/7-10\">",
"     7-10",
"    </a>",
"    ]. However, the electrocardiographic appearance of activation depends upon the extent of preexcitation and fusion and, as a result, the same pathway may not always produce the same ECG pattern. Furthermore, up to 13 percent of individuals with preexcitation have more than one accessory pathway [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17370/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In spite of the somewhat variable ECG findings associated with conduction over the accessory pathway, a left lateral pathway generally presents with a pseudo-lateral wall myocardial infarction (MI) pattern (Q wave in leads I and aVL), and a posteroseptal pathway most often presents with a pseudo-inferior wall MI pattern (Q wave in leads II, III and aVF). (See",
"    <a class=\"local\" href=\"#H13260510\">",
"     'Electrocardiographic (ECG) findings'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Associated cardiac abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with atrioventricular accessory pathways do not have coexisting structural cardiac abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17370/abstract/11\">",
"     11",
"    </a>",
"    ]. Associated congenital heart disease, when present, is more likely to be right-sided than left-sided in location [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17370/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Ebstein's anomaly is the congenital lesion most strongly associated with WPW syndrome. As many as 10 to 20 percent of such patients have one or more accessory pathway; the majority of these are located in the right free wall and right posteroseptal spaces [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17370/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/52/38729?source=see_link\">",
"     \"Ebstein's anomaly of the tricuspid valve\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An association between mitral valve prolapse and left-sided bypass tracts has also been reported. However, this association may simply reflect the random coexistence of two relatively common conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17370/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, a familial form of WPW is associated with hypertrophic cardiomyopathy. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Familial WPW'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PREVALENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;When discussing the prevalence of WPW, it is important to distinguish between the WPW pattern (ie, ECG abnormalities in asymptomatic patients) and WPW syndrome. Both are fairly infrequent, occurring in less than 1 percent of the general population, with the WPW pattern between 10 and 100 times more common than WPW syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Prevalence of WPW pattern",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of a WPW pattern on the surface ECG is estimated at 0.13 to 0.25 percent in the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17370/abstract/11,19,20\">",
"     11,19,20",
"    </a>",
"    ]. The prevalence appears higher (up to 0.55 percent) among first-degree relatives of persons with WPW pattern, suggesting a familial component. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Familial WPW'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The WPW pattern on the ECG may be intermittent and may even disappear permanently over time [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17370/abstract/19,21,22\">",
"     19,21,22",
"    </a>",
"    ]. In one cohort study, 22 percent of individuals who eventually manifested the WPW pattern on an ECG initially had a normal tracing, and in 40 percent of these patients the WPW pattern disappeared on subsequent ECGs [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17370/abstract/21\">",
"     21",
"    </a>",
"    ]. Similar findings have been noted in other smaller series [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17370/abstract/19,22\">",
"     19,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intermittent",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    persistent loss of preexcitation may indicate that the accessory pathway has a relatively longer baseline refractory period, which makes it more susceptible to age-related degenerative changes and variations in autonomic tone [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17370/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. Compared to patients with a persistent WPW pattern, those in whom antegrade conduction via the accessory pathway disappeared were older (50 versus 39 years) and had a longer refractory period of the accessory pathway at initial electrophysiologic study (414 versus 295 msec) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17370/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Prevalence of WPW syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of the WPW syndrome is substantially lower than that of the WPW pattern alone. The exact value has varied in different studies, depending in part upon the duration of follow-up:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a review of 22,500 healthy aviation personnel, the WPW pattern on an ECG was seen in 0.25 percent, and only 1.8 percent of these patients had documented arrhythmia [",
"      <a class=\"abstract\" href=\"UTD.htm?16/61/17370/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a report of 228 subjects with WPW pattern by ECG who were followed for 22 years, the overall incidence of arrhythmia resulting in WPW syndrome was 1 percent per year [",
"      <a class=\"abstract\" href=\"UTD.htm?16/61/17370/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study of 432,166 children, ages 6 to 20 years, the prevalence of WPW syndrome was 0.07 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?16/61/17370/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Different types of supraventricular arrhythmias occur in the WPW syndrome. Up to 80 percent of patients with arrhythmia have atrioventricular reentrant tachycardia, 15 to 30 percent have atrial fibrillation, and 5 percent have atrial flutter. The incidence of sudden cardiac death (SCD) is quite low, with a metaanalysis of twenty studies (1869 patients) estimating the risk at 0.13 percent per year [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17370/abstract/27\">",
"     27",
"    </a>",
"    ]. Most reports have found no cases of sudden death in asymptomatic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17370/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. However, one report noted three cases in 162 initially asymptomatic patients followed for five years; all three patients developed symptomatic atrial fibrillation before the episode of sudden death [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17370/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24311?source=see_link\">",
"     \"Atrioventricular reentrant tachycardia (AVRT) associated with an accessory pathway\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The occurrence of arrhythmia is related to the age at the time preexcitation was discovered [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17370/abstract/21,30\">",
"     21,30",
"    </a>",
"    ]. In one cohort study of 113 persons with WPW pattern, one-third of asymptomatic individuals less than 40 years of age at the time WPW pattern was identified eventually had symptomatic arrhythmias, compared with none of those who were 40 years of age or older at diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17370/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As noted above, the WPW pattern may disappear in asymptomatic patients; a similar course can occur in patients with the WPW syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17370/abstract/19,21,22\">",
"     19,21,22",
"    </a>",
"    ]. In one cohort of 113 patients with WPW syndrome or atrioventricular nodal reentrant tachycardia who were followed for nine years, 23 percent lost antegrade conduction and ventricular preexcitation, 8 percent lost retrograde conduction in the accessory pathway, and 10 percent had disappearance of their arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17370/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Prevalence of WPW pattern'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20061242\">",
"    <span class=\"h2\">",
"     Prevalence of concealed accessory pathways",
"    </span>",
"    &nbsp;&mdash;&nbsp;The true prevalence of concealed accessory pathways is unknown. Since the presence of a concealed accessory pathway is only identified during an arrhythmia (eg, atrioventricular reentrant tachycardia [AVRT]), such a pathway cannot be identified during sinus rhythm using an ECG alone. Thus, only patients with symptomatic arrhythmias who undergo diagnostic electrophysiologic studies ever have concealed accessory pathways diagnosed. Among patients with symptomatic supraventricular tachycardias presenting for catheter ablation, the prevalence of concealed accessory pathways is approximately 15 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17370/abstract/32-34\">",
"     32-34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     FAMILIAL WPW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with the WPW syndrome, 3.4 percent have first degree-relatives with a preexcitation syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17370/abstract/35\">",
"     35",
"    </a>",
"    ]. A familial form of WPW has infrequently been reported and is usually inherited as an autosomal dominant trait [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17370/abstract/6,36,37\">",
"     6,36,37",
"    </a>",
"    ]. Two studies of three families with affected subjects who had an early onset of conduction disease and frequent episodes of atrial fibrillation mapped the gene responsible for WPW to chromosome 7q34-q36 [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17370/abstract/36\">",
"     36",
"    </a>",
"    ]. Missense mutations were identified in the PRKAG2 gene, which encodes the gamma-2 regulatory subunit of AMP-activated protein kinase [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17370/abstract/36,37\">",
"     36,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An inherited form of WPW associated with familial hypertrophic cardiomyopathy has been described and may be due to either mutations in the PRKAG2 gene, as with isolated familial WPW, or in the LAMP2 gene, which is responsible for glycogen storage disease IIb (Danon disease). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/44/29386?source=see_link&amp;anchor=H17#H17\">",
"     \"Genetics of hypertrophic cardiomyopathy\", section on 'PRKAG2 and LAMP2 genes and WPW syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29400384\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, the majority of patients with the WPW pattern on their electrocardiogram (ECG) remain asymptomatic. However, a small percentage of patients with the WPW pattern develop arrhythmias (eg, atrial fibrillation with rapid ventricular response) as a part of the WPW syndrome. Most patients who develop an arrhythmia will present with one of more of the following symptoms:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Palpitations",
"     </li>",
"     <li>",
"      Lightheadedness",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      dizziness",
"     </li>",
"     <li>",
"      Syncope or presyncope",
"     </li>",
"     <li>",
"      Chest pain",
"     </li>",
"     <li>",
"      Sudden cardiac death",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8470608\">",
"    <span class=\"h2\">",
"     Arrhythmias associated with WPW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tachycardias associated with the WPW syndrome can be classified into those in which the accessory pathway is necessary for initiation and maintenance of the tachycardia and those in which the bypass tract acts as a \"bystander\", providing a route of conduction from the anatomic site of tachycardia origin to other regions of the heart (",
"    <a class=\"graphic graphic_figure graphicRef82249 \" href=\"UTD.htm?38/33/39441\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29400309\">",
"    <span class=\"h3\">",
"     Tachycardias requiring an accessory pathway for initiation and maintenance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrioventricular reentrant (or reciprocating) tachycardia (AVRT) is a reentrant tachycardia with an anatomically defined circuit that consists of two distinct pathways, the normal AV conduction system and an AV accessory pathway, linked by common proximal (the atria) and distal (the ventricles) tissues. If sufficient differences in conduction time and refractoriness exist between the normal conduction system and the bypass tract, a properly timed premature impulse of atrial, junctional, or ventricular origin can initiate reentry. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/62/42984?source=see_link\">",
"     \"Reentry and the development of cardiac arrhythmias\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The two major forms of this type of arrhythmia in the WPW syndrome are orthodromic and antidromic AVRT. The width of the QRS complex can usually distinguish between these paroxysmal arrhythmias. A full discussion of AVRT is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24311?source=see_link\">",
"     \"Atrioventricular reentrant tachycardia (AVRT) associated with an accessory pathway\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8472052\">",
"    <span class=\"h3\">",
"     Tachycardias not requiring an accessory pathway for initiation and maintenance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrial tachyarrhythmias, junctional tachycardias including atrioventricular nodal reentrant tachycardia (AVNRT), ventricular tachycardia and ventricular fibrillation can all occur in patients with an accessory pathway (",
"    <a class=\"graphic graphic_waveform graphicRef65336 \" href=\"UTD.htm?3/40/3718\">",
"     waveform 3",
"    </a>",
"    ). In these settings, the accessory pathway may serve as a route for ventricular or atrial activation but is generally not involved in the initiation of the arrhythmia and is not required for perpetuation of the arrhythmia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8471963\">",
"    <span class=\"h4\">",
"     Atrioventricular nodal reentrant tachycardia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrioventricular nodal reentrant tachycardia (AVNRT, also called junctional reciprocating tachycardia) can use the bystander accessory pathway to transmit impulses between the atrium to the ventricle (",
"    <a class=\"graphic graphic_figure graphicRef61702 \" href=\"UTD.htm?16/35/16944\">",
"     figure 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_waveform graphicRef65336 \" href=\"UTD.htm?3/40/3718\">",
"     waveform 3",
"    </a>",
"    ). When AVNRT occurs in the WPW syndrome, the arrhythmia cannot be distinguished from either antidromic or orthodromic AVRT without electrophysiologic studies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24793?source=see_link\">",
"     \"Atrioventricular nodal reentrant tachycardia (junctional reciprocating tachycardia)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8472027\">",
"    <span class=\"h4\">",
"     Atrial fibrillation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrial fibrillation (AF) occurs in 10 to 30 percent of persons with the WPW syndrome (",
"    <a class=\"graphic graphic_waveform graphicRef60790 \" href=\"UTD.htm?41/16/42250\">",
"     waveform 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_waveform graphicRef75523 \" href=\"UTD.htm?42/59/43962\">",
"     waveform 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17370/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. AF generally originates within the atria or pulmonary veins, independent of the accessory pathway, but the accessory pathway functions as another route for the conduction of atrial impulses to the ventricles. However, the 10 to 30 percent frequency with which intermittent AF occurs in patients with the WPW syndrome is striking because of the low prevalence of coexisting structural heart disease, which is a major predisposing factor for AF in subjects without an accessory pathway [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17370/abstract/18,38,40\">",
"     18,38,40",
"    </a>",
"    ]. This observation suggests that the AV accessory pathway itself may be related to the genesis of AF, perhaps due to retrograde conduction to the atrium at a time when it is vulnerable to the development of AF.",
"   </p>",
"   <p>",
"    Characteristic findings on the ECG in patients with AF and an accessory pathway include an irregularly irregular rhythm with QRS morphology changes from beat to beat and which may be associated with rapid AV transmission (",
"    <a class=\"graphic graphic_waveform graphicRef60790 \" href=\"UTD.htm?41/16/42250\">",
"     waveform 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_waveform graphicRef75523 \" href=\"UTD.htm?42/59/43962\">",
"     waveform 5",
"    </a>",
"    ). A sustained ventricular rate greater than 180 to 200 beats per minute can create \"pseudoregularized\" RR intervals when the ECG is recorded at standard speed (25 mm per second). When atrial impulses are transmitted along the accessory pathway in AF, ventricular rates may exceed 300 beats per minute and can degenerate into ventricular fibrillation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/42/26278?source=see_link\">",
"     \"The electrocardiogram in atrial fibrillation\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H8471569\">",
"     'Ventricular fibrillation and sudden death'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The QRS morphology and rate of impulse conduction during AF along the accessory pathway is dependent upon several factors, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The shorter the refractory period of the accessory pathway, the more rapid is antegrade impulse conduction and, because of more preexcitation, the QRS complexes are wider. Patients with very short refractory periods and rapid AF represent the group at greatest risk for degeneration to ventricular fibrillation. (See",
"      <a class=\"local\" href=\"#H8471569\">",
"       'Ventricular fibrillation and sudden death'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      The degree to which the AV",
"      <span class=\"nowrap\">",
"       node/His-Purkinje",
"      </span>",
"      system competes with the bypass tract for ventricular activation.",
"     </li>",
"     <li>",
"      Retrograde activation of the AP.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    AF is often preceded by atrioventricular reentrant tachycardia (AVRT) in individuals with WPW, with one report suggesting that as many as 35 percent of episodes of AF were preceded by AVRT [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17370/abstract/38,41,42\">",
"     38,41,42",
"    </a>",
"    ]. However, the mechanisms by which AVRT precipitates AF are not well understood, but increased stretching due to increased atrial pressure and conduction disturbances in atrial myocardium due to reduced refractoriness could play a role.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8471426\">",
"    <span class=\"h4\">",
"     Atrial flutter",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrial flutter is due to a reentrant circuit within the right atrium and therefore exists independently of the accessory pathway. Atrial flutter can, like atrial fibrillation, conduct antegrade via an accessory pathway causing a preexcited tachycardia (",
"    <a class=\"graphic graphic_figure graphicRef78602 \" href=\"UTD.htm?41/63/43002\">",
"     figure 4",
"    </a>",
"    ). Depending upon the various refractory periods of the normal and pathologic AV accessory pathways, atrial flutter potentially could conduct 1:1 to the ventricles during a preexcited tachycardia, making the arrhythmia difficult to distinguish from ventricular tachycardia. When atrial flutter is transmitted antegrade along the accessory pathway, ventricular rates may exceed 300 beats per minute and can degenerate into ventricular fibrillation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/19/31034?source=see_link\">",
"     \"Approach to the diagnosis and treatment of wide QRS complex tachycardias\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H8471569\">",
"     'Ventricular fibrillation and sudden death'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8471526\">",
"    <span class=\"h4\">",
"     Ventricular tachycardia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coexisting ventricular tachycardia is uncommon because patients with WPW syndrome infrequently have structural heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17370/abstract/12,18\">",
"     12,18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/14/26858?source=see_link\">",
"     \"Monomorphic ventricular tachycardia in the absence of apparent structural heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8471569\">",
"    <span class=\"h4\">",
"     Ventricular fibrillation and sudden death",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most cases, ventricular fibrillation (VF) occurring in patients with the WPW syndrome results from the rapid ventricular response during atrial fibrillation (AF) which has persisted and ultimately deteriorated into VF. Although the frequency with which AF with rapid AV conduction via an accessory pathway degenerates into VF is unknown, VF as the initial manifestation of WPW appears to be quite rare, occurring in only 8 of 690 patients with WPW in one single center cohort [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17370/abstract/43\">",
"     43",
"    </a>",
"    ]. Additionally, it is reassuring to note that the incidence of sudden death in patients with the WPW syndrome is quite low. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Prevalence of WPW syndrome'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Patients with the WPW pattern who appear to be at increased risk for VF include those with a history of AVRT",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    AF, those with a very short antegrade refractory period (&lt;250 msec) of the accessory pathway noted during electrophysiology studies, and those with short R-R intervals (&lt;250 msec) during an induced or spontaneous episode of atrial fibrillation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17370/abstract/30,44-47\">",
"     30,44-47",
"    </a>",
"    ]. In contrast, intermittent preexcitation, characterized by the intermittent loss of the delta wave, suggests that the bypass tract has a long refractory period, making the development of VF unlikely [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17370/abstract/47\">",
"     47",
"    </a>",
"    ]. However, preexcitation and arrhythmias have been previously undiagnosed in up to 25 percent of individuals with VF or sudden death [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17370/abstract/44,46,48\">",
"     44,46,48",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7844175\">",
"     'Electrophysiology testing'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Some medications, primarily AV nodal blockers (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    , adenosine,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    ), have been associated with an increased risk of VF in patients with preexcitation and AF due to preferential conduction via the accessory pathway. This is discussed in greater detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/60/15305?source=see_link\">",
"     \"Pharmacologic therapy of arrhythmias associated with the Wolff-Parkinson-White syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H249535\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of WPW pattern, which usually requires only a surface electrocardiogram (ECG), is typically prompted by an incidental finding on an ECG obtained for another clinical indication. Identification of a short PR interval and a delta wave is usually adequate to confirm the diagnosis of WPW pattern. In some rare circumstances, invasive electrophysiology testing can be helpful in confirming the diagnosis of an accessory pathway or detecting patients with short effective refractory periods (&lt;250ms), for example in competitive athletes. (See",
"    <a class=\"local\" href=\"#H13260510\">",
"     'Electrocardiographic (ECG) findings'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The diagnosis of WPW syndrome is typically made in a patient with a pre-existing WPW pattern on ECG who develops an arrhythmia which involves the accessory pathway, although some patients initially present with an arrhythmia and no known history of the WPW pattern. This diagnosis should be suspected in persons with an arrhythmia and a very rapid ventricular heart rate, particularly when a delta wave can be identified and particularly in children or young adults presenting a paroxysmal arrhythmia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H249527\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13260510\">",
"    <span class=\"h2\">",
"     Electrocardiographic (ECG) findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hallmark of AV accessory pathway function during sinus rhythm is",
"    <strong>",
"     preexcitation",
"    </strong>",
"    in which depolarization of all or part of the ventricles occurs via an accessory pathway (ie, by direct myocardial activation) that is separate from the normal AV conduction system and that occurs earlier than expected after atrial depolarization. This results in shortening of the PR interval, a delta wave, and widening of the QRS complex. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/61/13271?source=see_link\">",
"     \"General principles of asynchronous activation and preexcitation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29400392\">",
"    <span class=\"h3\">",
"     WPW pattern on ECG",
"    </span>",
"    &nbsp;&mdash;&nbsp;The classic ECG pattern of preexcitation in sinus rhythm is characterized by a fusion between conduction via the accessory pathway and the normal AV",
"    <span class=\"nowrap\">",
"     node/His-Purkinje",
"    </span>",
"    system. The classic electrocardiographic pattern of preexcitation in sinus rhythm in persons with either the WPW pattern or WPW syndrome (",
"    <a class=\"graphic graphic_waveform graphicRef75578 \" href=\"UTD.htm?34/55/35706\">",
"     waveform 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_waveform graphicRef76226 \" href=\"UTD.htm?35/41/36506\">",
"     waveform 2",
"    </a>",
"    ) has two major features:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The PR interval is short (less than 0.12 seconds) due to rapid AV conduction through the accessory pathway and bypass of the atrioventricular node.",
"     </li>",
"     <li>",
"      The QRS complex consists of fusion between early and direct ventricular myocardial activation caused by preexcitation and the later ventricular activation resulting from transmission through the AV node and the infranodal conduction system to the ventricles. While beginning earlier than expected, the initial part of ventricular activation is slowed, and the upstroke of the QRS complex is slurred because of slow muscle fiber-to-muscle fiber conduction. This is termed a",
"      <strong>",
"       delta wave",
"      </strong>",
"      . The more rapid the conduction along the accessory pathway, the greater the amount of myocardium depolarized via the accessory pathway, resulting in a more prominent or wider delta wave, and increasing prolongation of the QRS complex.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some accessory pathways do not conduct antegrade to the ventricles but instead are able to conduct retrograde from the ventricle to the atrium. Because there is no antegrade conduction over the accessory pathway, the characteristic ECG findings of the WPW pattern are absent. The diagnosis in patients with a concealed accessory pathway can only be made following ventricular ectopy or ventricular pacing or during electrophysiologic testing. (See",
"    <a class=\"local\" href=\"#H8470587\">",
"     'Normal AV conduction versus accessory AV pathway conduction'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H7844175\">",
"     'Electrophysiology testing'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Preexcitation and delta waves may not be apparent in sinus rhythm in patients with WPW who have a left-lateral bypass tract as the antegrade route for conduction. In this setting, the time for the atrial impulse to reach the atrial insertion of the accessory pathway is longer than the time to reach the AV node (",
"    <a class=\"graphic graphic_waveform graphicRef59047 \" href=\"UTD.htm?1/33/1557\">",
"     waveform 6",
"    </a>",
"    ), thereby minimizing preexcitation.",
"   </p>",
"   <p>",
"    Delta waves can occasionally be seen in patients with some atypical conduction pathways that do not connect in the usual atrioventricular fashion. One such pathway, sometimes referred to as a \"Mahaim fiber\", is now better understood to be an atriofascicular pathway. These pathways are found along the right lateral atrioventricular groove and run as a long conduction fiber along the right ventricular free-wall to approximate (or possibly connect to) the distal portion of the right bundle branch. Atriofascicular pathways only conduct in the anterograde direction but can participate in antidromic tachycardia using the normal conduction tissues as the retrograde limb of a circuit (",
"    <a class=\"graphic graphic_figure graphicRef61702 \" href=\"UTD.htm?16/35/16944\">",
"     figure 3",
"    </a>",
"    ). Clinical features of atypical conduction pathways are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/33/17943?source=see_link\">",
"     \"Mahaim fiber tachycardias\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Exercise uncommonly causes an abrupt loss of preexcitation as the sinus rate increases (",
"    <a class=\"graphic graphic_waveform graphicRef76833 \" href=\"UTD.htm?13/9/13463\">",
"     waveform 7",
"    </a>",
"    ). This is a reassuring but not absolute indicator that the accessory pathway is unlikely to conduct AF with a rapid ventricular response. More often, preexcitation becomes inapparent because increasing sympathetic and decreasing vagal tone enhances AV nodal conduction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20061034\">",
"    <span class=\"h3\">",
"     WPW pattern and ECG interpretation for other disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;The abnormal sequence of activation which occurs with electrical conduction via the accessory pathway gives rise to an abnormal sequence of repolarization, resulting in ST-T wave abnormalities. The vectors or direction of the secondary ST-T wave changes are usually directed opposite to the vectors of the delta wave and the QRS complex. As a result of the abnormal activation sequence, abnormalities affecting the ventricles, such as ischemia, infarction, hypertrophy, and pericarditis, may not always be reliably diagnosed in the presence of a WPW pattern.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7844175\">",
"    <span class=\"h2\">",
"     Electrophysiology testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The indications for electrophysiologic study (EPS) in patients with known or suspected WPW syndrome are still evolving. In most instances, EPS is",
"    <strong>",
"     not",
"    </strong>",
"    required to make the diagnosis of WPW pattern or syndrome, but EPS is sometimes combined with mapping and transcatheter ablation of the accessory pathway for both diagnostic and therapeutic purposes during the same session. We proceed with EPS in situations when the diagnosis is uncertain based on the surface ECG, for risk stratification purposes when a higher risk would alter the approach to therapy, and as part of a therapeutic catheter ablation procedure. Thus, for symptomatic patients with a history of one or more tachycardia events and manifest preexcitation on their ECG, EPS with ablation is now routinely offered early in the course of management as a potentially definitive treatment for the condition. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/60/15305?source=see_link\">",
"     \"Pharmacologic therapy of arrhythmias associated with the Wolff-Parkinson-White syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Invasive EPS is also strongly indicated in certain asymptomatic patients with a WPW pattern when there is a coexistent cardiac comorbidity. Conditions such as cardiomyopathy, coronary artery disease, significant valvular disease, and congenital heart defects will decrease tolerance to any abnormal rhythm and increase patient risk. Mapping and ablation will usually be done in all such cases to simplify cardiac management. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/42/27305?source=see_link&amp;anchor=H3#H3\">",
"     \"Electrophysiologic cardiac mapping: Use in specific arrhythmias\", section on 'Preexcitation syndromes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The more difficult decision involves otherwise healthy patients with preexcitation on their ECG but no symptoms (ie, WPW pattern) and no cardiac comorbidities. In such cases, the principle reasons for EPS are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      To confirm the diagnosis if doubt exists.",
"     </li>",
"     <li>",
"      To determine if the accessory pathway is capable of supporting reentrant tachycardia.",
"     </li>",
"     <li>",
"      To measure the conduction characteristics of the accessory pathway in an effort to estimate the patient's risk for rapid conduction if an episode of atrial fibrillation were to develop in the future.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In essence, EPS is used in asymptomatic patients with the WPW pattern as a risk-stratification tool, with ablation added if that risk is deemed to be high [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17370/abstract/11\">",
"     11",
"    </a>",
"    ]. Before proceeding with EPS for this purpose, it may be possible to estimate risk in some cases by less invasive means. The observation of an abrupt and unambiguous loss of preexcitation at faster sinus rates on ECG, Holter monitor, or exercise testing may be a sufficient sign that the accessory pathway has limited anterograde conduction potential and is unlikely to result in life-threatening ventricular rates during atrial fibrillation. Expert consensus is that these \"low-risk\" patients can usually be followed without invasive testing as long as they remain asymptomatic.",
"   </p>",
"   <p>",
"    If preexcitation persists at maximum heart rates during exercise testing, it does not necessarily mean that the patient is \"high-risk\", but rather that the risk cannot be determined by noninvasive means. A decision to proceed to EPS in these indeterminate cases for better resolution of accessory pathway profile must be made on a case-by-case basis with careful discussion between clinician and patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H249793\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13260518\">",
"    <span class=\"h2\">",
"     Differential diagnosis of ECG findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;The electrocardiographic (ECG) findings in persons with the WPW pattern can be similar to ECG findings seen in other cardiac conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17370/abstract/49\">",
"     49",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Myocardial infarction &ndash; A negative delta wave (presenting as a Q wave) may mimic a myocardial infarction pattern. Conversely, a positive delta wave may mask the presence of a previous myocardial infarction. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/6/9317?source=see_link\">",
"       \"ECG tutorial: Myocardial infarction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Ventricular premature beats or idioventricular rhythm &ndash; Intermittent WPW may be mistaken for frequent ventricular premature beats. The WPW pattern is occasionally seen on alternate beats and may suggest ventricular bigeminy. If the WPW pattern persists for several beats, the rhythm may be misdiagnosed as an accelerated idioventricular rhythm. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/6/9320?source=see_link\">",
"       \"Prevalence and evaluation of ventricular premature beats\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/57/1942?source=see_link&amp;anchor=H11#H11\">",
"       \"ECG tutorial: Ventricular arrhythmias\", section on 'Accelerated idioventricular rhythm'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      An alternating WPW and normal pattern may occasionally suggest electrical alternans. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/7/23669?source=see_link&amp;anchor=H10#H10\">",
"       \"Electrocardiogram in pericarditis and pericardial effusion\", section on 'Electrocardiogram in pericardial effusion'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Bundle branch block &ndash; The QRS duration is equal to or greater than 0.12 sec because of preexcitation (ie, the delta wave). Preexcited beats are sometimes confused with left or right bundle branch block as a result. However, the terminal portion of the QRS is usually normal, due to normal conduction through the AV node and ventricular activation via the Purkinje system. This is in contrast to intraventricular conduction defects such as right or left bundle branch block in which the conduction delay occurs in either the terminal portion of or throughout the QRS complex. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10344?source=see_link&amp;anchor=H14316065#H14316065\">",
"       \"Right bundle branch block\", section on 'Electrocardiographic findings'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/54/39784?source=see_link&amp;anchor=H618500#H618500\">",
"       \"Left bundle branch block\", section on 'Electrocardiographic findings'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Some patients with cardiomyopathy and certain congenital heart defects (eg, single ventricle) may have atrial enlargement combined with abnormal ventricular activation that can result in a pattern of \"pseudo-preexcitation\". Some cases of hypertrophic cardiomyopathy may mimic a WPW pattern as the PR is often short and the QRS widened because of hypertrophy [",
"      <a class=\"abstract\" href=\"UTD.htm?16/61/17370/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H249830\">",
"    <span class=\"h2\">",
"     Differential diagnosis of supraventricular tachycardia with very rapid ventricular response",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis for supraventricular tachycardia (SVT) with a rapid ventricular response is fairly extensive and is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39481?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical manifestations, diagnosis, and evaluation of narrow QRS complex tachycardias\", section on 'Types of narrow QRS complex tachycardia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, the differential diagnosis of SVT with a very rapid ventricular response (greater than 180 to 200 beats per minute in adults, higher than 200 beats per minute in children) is somewhat narrower. Because of the conduction properties and refractoriness of the AV node, and because the intrinsic rate of most types of SVT (eg, sinus tachycardia, AV nodal reentrant tachycardia, inappropriate sinus tachycardia) is less than 200 beats per minute, SVT which traverses the AV node in an antegrade direction will rarely achieve heart rates greater than 180 to 200 beats per minute. An SVT which is not dependent on the AV node, or one with a markedly faster intrinsic rate, however, may reach much faster heart rates. Examples of this include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Atrial fibrillation with accessory pathway conduction",
"     </li>",
"     <li>",
"      Atrial flutter with accessory pathway conduction",
"     </li>",
"     <li>",
"      Atrioventricular reentrant tachycardia (AVRT)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3789106\">",
"    <span class=\"h1\">",
"     RISK STRATIFICATION OF ASYMPTOMATIC PATIENTS WITH WPW PATTERN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who initially present with the WPW pattern on surface electrocardiogram (ECG) but without a symptomatic arrhythmia represent a significant clinical challenge with regard to risk stratification and management. While the majority of such asymptomatic WPW patients, who are often young and otherwise healthy, will remain asymptomatic, reported rates of symptomatic arrhythmia development have been as high as 20 percent over three years [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17370/abstract/30\">",
"     30",
"    </a>",
"    ]. One approach to asymptomatic patients with WPW syndrome is risk stratification using noninvasive tests",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    an electrophysiologic (EP) study to identify those patients at greatest risk [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17370/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanism of sudden cardiac death (SCD) in patients with WPW syndrome is ventricular fibrillation (VF), which generally occurs during an episode of atrial fibrillation in which there is frequent conduction to the ventricle, leading to an excessively rapid ventricular response that degenerates into VF. Identifying asymptomatic patients at the greatest risk for VF would provide a rationale for more aggressive therapy (eg, catheter ablation).",
"   </p>",
"   <p>",
"    There is conflicting evidence as to which findings predict the development of symptoms",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    SCD. Some of the findings that have been suggested to predict a higher likelihood of symptoms include [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17370/abstract/47,51,52\">",
"     47,51,52",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Younger age",
"     </li>",
"     <li>",
"      Male gender",
"     </li>",
"     <li>",
"      Inducible AVRT or AF during EP study",
"     </li>",
"     <li>",
"      Multiple accessory pathways",
"     </li>",
"     <li>",
"      Short refractory period of the accessory pathway",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The refractory period refers to the amount of time required after one conducted impulse for the accessory pathway (or any cardiac tissue) to \"reset\" and be able to conduct a subsequent impulse. This characteristic often defines how frequently an accessory pathway can conduct to the ventricle.",
"   </p>",
"   <p>",
"    Risk stratification of asymptomatic patients with the WPW pattern can be performed noninvasively or via invasive electrophysiology (EP) study.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Noninvasive evaluation &ndash; Although the refractory period of an accessory pathway is usually measured during an EP study, patients with an accessory pathway that has a long refractory period can often be identified noninvasively. Intermittent loss of preexcitation (as detected by loss of delta wave on ECG) suggests that the accessory pathway has a long refractory period and will not be able to conduct frequently enough during AF to produce ventricular fibrillation. Intermittent preexcitation or loss of preexcitation may be seen in the following settings:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Resting ECG",
"     </li>",
"     <li>",
"      At increased heart rates during exercise",
"     </li>",
"     <li>",
"      Following intravenous administration of a sodium channel blocker, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"       procainamide",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One suggested approach in asymptomatic patients is to perform noninvasive studies (eg, exercise testing or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    challenge) to identify those at low risk who would require no further evaluation or treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17370/abstract/11,53\">",
"     11,53",
"    </a>",
"    ]. Patients without these low-risk findings, particularly those under age 35 to 40, could then consider further risk stratification and treatment with invasive EP study. Decisions to proceed would be based upon the patient's values, occupation, and activity level.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Invasive EP study &ndash; An alternative approach to noninvasive risk stratification is to proceed directly to EP study as an initial means of risk stratification in all patients with an asymptomatic WPW ECG pattern. Among a cohort of 224 asymptomatic patients with ventricular preexcitation, 76 patients aged 35 years or less were found to have inducible atrioventricular reentrant tachycardia or atrial fibrillation during EP study and were randomly assigned to catheter ablation (37 patients, median follow up 27 months) of the accessory pathway or no therapy (35 patients, median follow-up 21 months) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/61/17370/abstract/54\">",
"       54",
"      </a>",
"      ]. In the ablation group, only two patients (5 percent) had arrhythmic events, both due to a mechanism that was unrelated to the ablated accessory pathway (atrioventricular nodal reentrant tachycardia), while in the control group, 21 patients (60 percent) had arrhythmic events (VF in one patient, supraventricular tachycardia in 15 patients, and AF in five patients). The five-year estimated incidence of arrhythmic events was significantly lower for patients treated with ablation than for controls (7 versus 77 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In summary, initial risk-stratification with EP study successfully identified those with a higher likelihood of developing symptoms, and treatment of these high risk patients with ablation reduced arrhythmic events [",
"    <a class=\"abstract\" href=\"UTD.htm?16/61/17370/abstract/11\">",
"     11",
"    </a>",
"    ]. However, life-threatening arrhythmias were rare in the absence of ablation and serious complications developed in 2 percent of patients undergoing risk stratification. Thus, it remains unknown whether initial risk stratification with EP study produces a net reduction in morbidity or mortality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?22/56/23427?source=see_link\">",
"       \"Patient information: Wolff-Parkinson-White syndrome (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?8/50/8995?source=see_link\">",
"       \"Patient information: Wolff-Parkinson-White syndrome (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H158486\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Wolff-Parkinson-White (WPW) syndrome is a syndrome of intermittent tachycardia in patients with a short PR interval and a widened QRS complex on their electrocardiogram (ECG). WPW syndrome results from an accessory pathway that directly connects the atria and ventricles and bypasses the AV node. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most accessory pathways are capable of antegrade conduction (either antegrade conduction alone or bidirectional conduction) from atrium to ventricle; however, some accessory pathways conduct only in a retrograde fashion from ventricle to atrium. Because there is no antegrade conduction through the accessory pathway, the characteristic WPW ECG pattern is absent, and the pathway is considered to be \"concealed\". (See",
"      <a class=\"local\" href=\"#H8470587\">",
"       'Normal AV conduction versus accessory AV pathway conduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The accessory pathway may be located anywhere along the AV ring (groove) or in the septum. The most frequent locations are left lateral (50 percent), posteroseptal (30 percent), right anteroseptal (10 percent), and right lateral (10 percent). (See",
"      <a class=\"local\" href=\"#H13260635\">",
"       'Anatomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The prevalence of a WPW pattern on the surface ECG is estimated at 0.13 to 0.25 percent in the general population. The WPW pattern on the ECG may be intermittent and may even disappear permanently over time, depending on the conduction properties of the accessory pathway. The prevalence of the WPW syndrome (WPW pattern plus tachyarrhythmia) is substantially lower than that of the WPW pattern alone, perhaps as low as two percent of patients with the WPW pattern on surface ECG. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Prevalence of WPW pattern'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Prevalence of WPW syndrome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The classic ECG pattern of preexcitation in sinus rhythm is characterized by a fusion between conduction via the accessory pathway and the normal AV",
"      <span class=\"nowrap\">",
"       node/His-Purkinje",
"      </span>",
"      system, resulting in the following ECG characteristics (see",
"      <a class=\"local\" href=\"#H13260510\">",
"       'Electrocardiographic (ECG) findings'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The PR interval is short (less than 0.12 sec) due to rapid AV conduction through the accessory pathway and bypass of the atrioventricular node.",
"     </li>",
"     <li>",
"      The initial part of ventricular activation is slowed, and the upstroke of the QRS complex is slurred because of slow muscle fiber-to-muscle fiber conduction; this is termed a",
"      <strong>",
"       delta wave.",
"      </strong>",
"     </li>",
"     <li>",
"      The QRS complex is widened and consists of fusion between early ventricular activation caused by preexcitation with the later ventricular activation resulting from transmission through the AV node and the infranodal conduction system to the ventricles.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The majority of patients with the WPW pattern on their electrocardiogram (ECG) remain asymptomatic, although a small percentage of patients with the WPW pattern develop arrhythmias as a part of the WPW syndrome. Most patients who develop an arrhythmia will present with palpitations, with syncope or sudden cardiac death occurring much less frequently. (See",
"      <a class=\"local\" href=\"#H29400384\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Tachycardias associated with the WPW syndrome can be classified into those in which the accessory pathway is necessary for initiation and maintenance of the tachycardia and those in which the bypass tract acts as a \"bystander\", providing a route of conduction from the anatomic site of tachycardia origin to other regions of the heart:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Atrioventricular reentrant (or reciprocating) tachycardia (AVRT) is a reentrant tachycardia with an anatomically defined circuit that consists of two distinct pathways, the normal AV conduction system and an AV accessory pathway, linked by common proximal (the atria) and distal (the ventricles) tissues. The two major forms of AVRT are orthodromic and antidromic AVRT, defined by the direction of conduction through the AV node and the accessory pathway. (See",
"      <a class=\"local\" href=\"#H29400309\">",
"       'Tachycardias requiring an accessory pathway for initiation and maintenance'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24311?source=see_link\">",
"       \"Atrioventricular reentrant tachycardia (AVRT) associated with an accessory pathway\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Atrial fibrillation (AF) occurs in 10 to 30 percent of persons with the WPW syndrome, somewhat higher than might be expected given the low prevalence of coexisting structural heart disease. When atrial impulses are transmitted along the accessory pathway in AF, ventricular rates may exceed 300 beats per minute and can degenerate into ventricular fibrillation (VF). (See",
"      <a class=\"local\" href=\"#H8472027\">",
"       'Atrial fibrillation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In most cases, VF occurring in patients with the WPW syndrome results from the rapid ventricular response during AF which has persisted and ultimately deteriorated into VF. Although the frequency with which AF with rapid AV conduction via an accessory pathway degenerates into VF is unknown, the incidence of sudden death in patients with the WPW syndrome is quite low. (See",
"      <a class=\"local\" href=\"#H8471569\">",
"       'Ventricular fibrillation and sudden death'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The diagnosis of WPW pattern can nearly always be made by reviewing the surface ECG. In addition, in some rare circumstances invasive electrophysiology testing can be helpful in confirming the diagnosis of an accessory pathway. WPW syndrome is diagnosed following the development of an arrhythmia in a patient with a pre-existing WPW pattern on ECG. (See",
"      <a class=\"local\" href=\"#H249535\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The indications for electrophysiologic study (EPS) in patients with known or suspected WPW syndrome are still evolving. In most instances, EPS is",
"      <strong>",
"       not",
"      </strong>",
"      required to make the diagnosis of WPW pattern or syndrome, but EPS is sometimes combined with mapping and transcatheter ablation of the accessory pathway for both diagnostic and therapeutic purposes during the same session. We proceed with EPS in situations when the diagnosis is uncertain based on the surface ECG, for risk stratification purposes when a higher risk would alter the approach to therapy, and as part of a therapeutic catheter ablation procedure. (See",
"      <a class=\"local\" href=\"#H7844175\">",
"       'Electrophysiology testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The electrocardiographic (ECG) findings in persons with the WPW pattern can be similar to ECG findings seen in other cardiac conditions, including prior myocardial infarction, ventricular premature beats, idioventricular rhythm, and bundle branch block. (See",
"      <a class=\"local\" href=\"#H13260518\">",
"       'Differential diagnosis of ECG findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For certain asymptomatic patients with preexcitation, including children, those with a very short refractory period of the accessory pathway, and those in high-risk professions involving risk to themselves and others, we suggest electrophysiology study and ablation (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3789106\">",
"       'Risk stratification of asymptomatic patients with WPW pattern'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/60/15305?source=see_link\">",
"       \"Pharmacologic therapy of arrhythmias associated with the Wolff-Parkinson-White syndrome\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H826207458\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The authors and UpToDate would like to thank Dr. Philip Podrid, who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17370/abstract/1\">",
"      Wolff L, Parkinson J, White PD. Bundle-branch block with short P-R interval in healthy young people prone to paroxysmal tachycardia. 1930. Ann Noninvasive Electrocardiol 2006; 11:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17370/abstract/2\">",
"      Miller JM. Therapy of Wolff-Parkinson-White syndrome and concealed bypass tracts: Part I. J Cardiovasc Electrophysiol 1996; 7:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17370/abstract/3\">",
"      Kuck KH, Friday KJ, Kunze KP, et al. Sites of conduction block in accessory atrioventricular pathways. Basis for concealed accessory pathways. Circulation 1990; 82:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17370/abstract/4\">",
"      Colavita PG, Packer DL, Pressley JC, et al. Frequency, diagnosis and clinical characteristics of patients with multiple accessory atrioventricular pathways. Am J Cardiol 1987; 59:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17370/abstract/5\">",
"      Zachariah JP, Walsh EP, Triedman JK, et al. Multiple accessory pathways in the young: the impact of structural heart disease. Am Heart J 2013; 165:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17370/abstract/6\">",
"      Vidaillet HJ Jr, Pressley JC, Henke E, et al. Familial occurrence of accessory atrioventricular pathways (preexcitation syndrome). N Engl J Med 1987; 317:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17370/abstract/7\">",
"      Milstein S, Sharma AD, Guiraudon GM, Klein GJ. An algorithm for the electrocardiographic localization of accessory pathways in the Wolff-Parkinson-White syndrome. Pacing Clin Electrophysiol 1987; 10:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17370/abstract/8\">",
"      Fitzpatrick AP, Gonzales RP, Lesh MD, et al. New algorithm for the localization of accessory atrioventricular connections using a baseline electrocardiogram. J Am Coll Cardiol 1994; 23:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17370/abstract/9\">",
"      Reddy GV, Schamroth L. The localization of bypass tracts in the Wolff-Parkinson-White syndrome from the surface electrocardiogram. Am Heart J 1987; 113:984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17370/abstract/10\">",
"      Epstein AE, Kirklin JK, Holman WL, et al. Intermediate septal accessory pathways: electrocardiographic characteristics, electrophysiologic observations and their surgical implications. J Am Coll Cardiol 1991; 17:1570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17370/abstract/11\">",
"      Pediatric and Congenital Electrophysiology Society (PACES), Heart Rhythm Society (HRS), American College of Cardiology Foundation (ACCF), et al. PACES/HRS expert consensus statement on the management of the asymptomatic young patient with a Wolff-Parkinson-White (WPW, ventricular preexcitation) electrocardiographic pattern: developed in partnership between the Pediatric and Congenital Electrophysiology Society (PACES) and the Heart Rhythm Society (HRS). Endorsed by the governing bodies of PACES, HRS, the American College of Cardiology Foundation (ACCF), the American Heart Association (AHA), the American Academy of Pediatrics (AAP), and the Canadian Heart Rhythm Society (CHRS). Heart Rhythm 2012; 9:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17370/abstract/12\">",
"      Deal BJ, Keane JF, Gillette PC, Garson A Jr. Wolff-Parkinson-White syndrome and supraventricular tachycardia during infancy: management and follow-up. J Am Coll Cardiol 1985; 5:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17370/abstract/13\">",
"      SCHIEBLER GL, ADAMS P Jr, ANDERSON RC. The Wolff-Parkinson-White syndrome in infants and children. A review and a report of 28 cases. Pediatrics 1959; 24:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17370/abstract/14\">",
"      LEV M, GIBSON S, MILLER RA. Ebstein's disease with Wolff-Parkinson-White syndrome; report of a case with a histopathologic study of possible conduction pathways. Am Heart J 1955; 49:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17370/abstract/15\">",
"      Cappato R, Schl&uuml;ter M, Weiss C, et al. Radiofrequency current catheter ablation of accessory atrioventricular pathways in Ebstein's anomaly. Circulation 1996; 94:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17370/abstract/16\">",
"      Attenhofer Jost CH, Connolly HM, O'Leary PW, et al. Left heart lesions in patients with Ebstein anomaly. Mayo Clin Proc 2005; 80:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17370/abstract/17\">",
"      Gallagher JJ, Pritchett EL, Sealy WC, et al. The preexcitation syndromes. Prog Cardiovasc Dis 1978; 20:285.",
"     </a>",
"    </li>",
"    <li>",
"     Josephson ME. Preexcitation syndromes. In: Clinical Cardiac Electrophysiology, 4th, Lippincot Williams &amp; Wilkins, Philadelphia 2008. p.339.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17370/abstract/19\">",
"      Krahn AD, Manfreda J, Tate RB, et al. The natural history of electrocardiographic preexcitation in men. The Manitoba Follow-up Study. Ann Intern Med 1992; 116:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17370/abstract/20\">",
"      Kobza R, Toggweiler S, Dillier R, et al. Prevalence of preexcitation in a young population of male Swiss conscripts. Pacing Clin Electrophysiol 2011; 34:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17370/abstract/21\">",
"      Munger TM, Packer DL, Hammill SC, et al. A population study of the natural history of Wolff-Parkinson-White syndrome in Olmsted County, Minnesota, 1953-1989. Circulation 1993; 87:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17370/abstract/22\">",
"      Klein GJ, Yee R, Sharma AD. Longitudinal electrophysiologic assessment of asymptomatic patients with the Wolff-Parkinson-White electrocardiographic pattern. N Engl J Med 1989; 320:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17370/abstract/23\">",
"      Klein GJ, Gulamhusein SS. Intermittent preexcitation in the Wolff-Parkinson-White syndrome. Am J Cardiol 1983; 52:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17370/abstract/24\">",
"      SMITH RF. THE WOLFF-PARKINSON-WHITE SYNDROME AS AN AVIATION RISK. Circulation 1964; 29:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17370/abstract/25\">",
"      Fitzsimmons PJ, McWhirter PD, Peterson DW, Kruyer WB. The natural history of Wolff-Parkinson-White syndrome in 228 military aviators: a long-term follow-up of 22 years. Am Heart J 2001; 142:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17370/abstract/26\">",
"      Chiu SN, Wang JK, Wu MH, et al. Cardiac conduction disturbance detected in a pediatric population. J Pediatr 2008; 152:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17370/abstract/27\">",
"      Obeyesekere MN, Leong-Sit P, Massel D, et al. Risk of arrhythmia and sudden death in patients with asymptomatic preexcitation: a meta-analysis. Circulation 2012; 125:2308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17370/abstract/28\">",
"      Leitch JW, Klein GJ, Yee R, Murdock C. Prognostic value of electrophysiology testing in asymptomatic patients with Wolff-Parkinson-White pattern. Circulation 1990; 82:1718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17370/abstract/29\">",
"      Todd DM, Klein GJ, Krahn AD, et al. Asymptomatic Wolff-Parkinson-White syndrome: is it time to revisit guidelines? J Am Coll Cardiol 2003; 41:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17370/abstract/30\">",
"      Pappone C, Santinelli V, Rosanio S, et al. Usefulness of invasive electrophysiologic testing to stratify the risk of arrhythmic events in asymptomatic patients with Wolff-Parkinson-White pattern: results from a large prospective long-term follow-up study. J Am Coll Cardiol 2003; 41:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17370/abstract/31\">",
"      Chen SA, Chiang CE, Tai CT, et al. Longitudinal clinical and electrophysiological assessment of patients with symptomatic Wolff-Parkinson-White syndrome and atrioventricular node reentrant tachycardia. Circulation 1996; 93:2023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17370/abstract/32\">",
"      Calkins H, Sousa J, el-Atassi R, et al. Diagnosis and cure of the Wolff-Parkinson-White syndrome or paroxysmal supraventricular tachycardias during a single electrophysiologic test. N Engl J Med 1991; 324:1612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17370/abstract/33\">",
"      Kay GN, Epstein AE, Dailey SM, Plumb VJ. Role of radiofrequency ablation in the management of supraventricular arrhythmias: experience in 760 consecutive patients. J Cardiovasc Electrophysiol 1993; 4:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17370/abstract/34\">",
"      Farshidi A, Josephson ME, Horowitz LN. Electrophysiologic characteristics of concealed bypass tracts: clinical and electrocardiographic correlates. Am J Cardiol 1978; 41:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17370/abstract/35\">",
"      Massumi RA. Familial Wolff-Parkinson-White syndrome with cardiomyopathy. Am J Med 1967; 43:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17370/abstract/36\">",
"      Gollob MH, Green MS, Tang AS, et al. Identification of a gene responsible for familial Wolff-Parkinson-White syndrome. N Engl J Med 2001; 344:1823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17370/abstract/37\">",
"      Gollob MH, Seger JJ, Gollob TN, et al. Novel PRKAG2 mutation responsible for the genetic syndrome of ventricular preexcitation and conduction system disease with childhood onset and absence of cardiac hypertrophy. Circulation 2001; 104:3030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17370/abstract/38\">",
"      Campbell RW, Smith RA, Gallagher JJ, et al. Atrial fibrillation in the preexcitation syndrome. Am J Cardiol 1977; 40:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17370/abstract/39\">",
"      Sharma AD, Klein GJ, Guiraudon GM, Milstein S. Atrial fibrillation in patients with Wolff-Parkinson-White syndrome: incidence after surgical ablation of the accessory pathway. Circulation 1985; 72:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17370/abstract/40\">",
"      Wellens HJ, Durrer D. Wolff-Parkinson-White syndrome and atrial fibrillation. Relation between refractory period of accessory pathway and ventricular rate during atrial fibrillation. Am J Cardiol 1974; 34:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17370/abstract/41\">",
"      Sung RJ, Castellanos A, Mallon SM, et al. Mechanisms of spontaneous alternation between reciprocating tachycardia and atrial flutter-fibrillation in the Wolff-Parkinson-White syndrome. Circulation 1977; 56:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17370/abstract/42\">",
"      Fujimura O, Klein GJ, Yee R, Sharma AD. Mode of onset of atrial fibrillation in the Wolff-Parkinson-White syndrome: how important is the accessory pathway? J Am Coll Cardiol 1990; 15:1082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17370/abstract/43\">",
"      Timmermans C, Smeets JL, Rodriguez LM, et al. Aborted sudden death in the Wolff-Parkinson-White syndrome. Am J Cardiol 1995; 76:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17370/abstract/44\">",
"      Klein GJ, Bashore TM, Sellers TD, et al. Ventricular fibrillation in the Wolff-Parkinson-White syndrome. N Engl J Med 1979; 301:1080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17370/abstract/45\">",
"      Oren JW 4th, Beckman KJ, McClelland JH, et al. A functional approach to the preexcitation syndromes. Cardiol Clin 1993; 11:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17370/abstract/46\">",
"      Montoya PT, Brugada P, Smeets J, et al. Ventricular fibrillation in the Wolff-Parkinson-White syndrome. Eur Heart J 1991; 12:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17370/abstract/47\">",
"      Blomstr&ouml;m-Lundqvist C, Scheinman MM, Aliot EM, et al. ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Supraventricular Arrhythmias). Circulation 2003; 108:1871.",
"     </a>",
"    </li>",
"    <li>",
"     Yee, R, Klein, GJ, Sharma, AD, et, al. Tachycardia associated with accessory atrioventricular pathways. In: Cardiac Electrophysiology, Zipes, DP, Jalife, J (Eds), WB Saunders, Philadelphia 1990. p.463.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17370/abstract/49\">",
"      Wang K, Asinger R, Hodges M. Electrocardiograms of Wolff-Parkinson-White syndrome simulating other conditions. Am Heart J 1996; 132:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17370/abstract/50\">",
"      Sternick EB. Familial pseudo-WPW syndrome. J Cardiovasc Electrophysiol 2009; 20:E62; author reply E63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17370/abstract/51\">",
"      Wellens HJ. Should catheter ablation be performed in asymptomatic patients with Wolff-Parkinson-White syndrome? When to perform catheter ablation in asymptomatic patients with a Wolff-Parkinson-White electrocardiogram. Circulation 2005; 112:2201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17370/abstract/52\">",
"      Pappone C, Santinelli V. Should catheter ablation be performed in asymptomatic patients with Wolff-Parkinson-White syndrome? Catheter ablation should be performed in asymptomatic patients with Wolff-Parkinson-White syndrome. Circulation 2005; 112:2207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17370/abstract/53\">",
"      Mehta D, Wafa S, Ward DE, Camm AJ. Relative efficacy of various physical manoeuvres in the termination of junctional tachycardia. Lancet 1988; 1:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/61/17370/abstract/54\">",
"      Pappone C, Santinelli V, Manguso F, et al. A randomized study of prophylactic catheter ablation in asymptomatic patients with the Wolff-Parkinson-White syndrome. N Engl J Med 2003; 349:1803.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 962 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-2.133.93.82-3DA446CC7F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_61_17370=[""].join("\n");
var outline_f16_61_17370=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H158486\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8470587\">",
"      Normal AV conduction versus accessory AV pathway conduction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13260536\">",
"      WPW pattern versus WPW syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13260635\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8470594\">",
"      Accessory pathway location",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Associated cardiac abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PREVALENCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Prevalence of WPW pattern",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Prevalence of WPW syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20061242\">",
"      Prevalence of concealed accessory pathways",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      FAMILIAL WPW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29400384\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8470608\">",
"      Arrhythmias associated with WPW",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29400309\">",
"      - Tachycardias requiring an accessory pathway for initiation and maintenance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8472052\">",
"      - Tachycardias not requiring an accessory pathway for initiation and maintenance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H8471963\">",
"      Atrioventricular nodal reentrant tachycardia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H8472027\">",
"      Atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H8471426\">",
"      Atrial flutter",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H8471526\">",
"      Ventricular tachycardia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H8471569\">",
"      Ventricular fibrillation and sudden death",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H249535\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H249527\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13260510\">",
"      Electrocardiographic (ECG) findings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29400392\">",
"      - WPW pattern on ECG",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20061034\">",
"      - WPW pattern and ECG interpretation for other disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7844175\">",
"      Electrophysiology testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H249793\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13260518\">",
"      Differential diagnosis of ECG findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H249830\">",
"      Differential diagnosis of supraventricular tachycardia with very rapid ventricular response",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3789106\">",
"      RISK STRATIFICATION OF ASYMPTOMATIC PATIENTS WITH WPW PATTERN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H158486\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H826207458\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/962\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/962|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/5/23634\" title=\"figure 1\">",
"      Anatomy AV accessory pathways",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/33/39441\" title=\"figure 2\">",
"      Sites of reentry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/35/16944\" title=\"figure 3\">",
"      Mechanisms Mahaim tachy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/63/43002\" title=\"figure 4\">",
"      ECG atrial flutter preexcitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/962|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/0/26635\" title=\"table 1\">",
"      Terminology of preexcitation pathways",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/962|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?34/55/35706\" title=\"waveform 1\">",
"      ECG WPW tutorial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?35/41/36506\" title=\"waveform 2\">",
"      ECG sinus rhythm WPW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?3/40/3718\" title=\"waveform 3\">",
"      EPS tracings AVRT into atrial tachycardia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?41/16/42250\" title=\"waveform 4\">",
"      ECG atrial fibrillation in WPW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?42/59/43962\" title=\"waveform 5\">",
"      ECG with atrial fibrillation with preexcitation in WPW syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?1/33/1557\" title=\"waveform 6\">",
"      ECG_Left lateral WPW III",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?13/9/13463\" title=\"waveform 7\">",
"      ECG exercise changes on ECG in WPW",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/21/39256?source=related_link\">",
"      Anatomy, pathophysiology and localization of accessory pathways in the preexcitation syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/19/31034?source=related_link\">",
"      Approach to the diagnosis and treatment of wide QRS complex tachycardias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24793?source=related_link\">",
"      Atrioventricular nodal reentrant tachycardia (junctional reciprocating tachycardia)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24311?source=related_link\">",
"      Atrioventricular reentrant tachycardia (AVRT) associated with an accessory pathway",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39481?source=related_link\">",
"      Clinical manifestations, diagnosis, and evaluation of narrow QRS complex tachycardias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/6/9317?source=related_link\">",
"      ECG tutorial: Myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/57/1942?source=related_link\">",
"      ECG tutorial: Ventricular arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/52/38729?source=related_link\">",
"      Ebstein's anomaly of the tricuspid valve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/7/23669?source=related_link\">",
"      Electrocardiogram in pericarditis and pericardial effusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/42/27305?source=related_link\">",
"      Electrophysiologic cardiac mapping: Use in specific arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/61/13271?source=related_link\">",
"      General principles of asynchronous activation and preexcitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/44/29386?source=related_link\">",
"      Genetics of hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/54/39784?source=related_link\">",
"      Left bundle branch block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/0/11272?source=related_link\">",
"      Lown-Ganong-Levine syndrome and enhanced atrioventricular nodal conduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/33/17943?source=related_link\">",
"      Mahaim fiber tachycardias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/14/26858?source=related_link\">",
"      Monomorphic ventricular tachycardia in the absence of apparent structural heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?8/50/8995?source=related_link\">",
"      Patient information: Wolff-Parkinson-White syndrome (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/56/23427?source=related_link\">",
"      Patient information: Wolff-Parkinson-White syndrome (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/60/15305?source=related_link\">",
"      Pharmacologic therapy of arrhythmias associated with the Wolff-Parkinson-White syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/6/9320?source=related_link\">",
"      Prevalence and evaluation of ventricular premature beats",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/62/42984?source=related_link\">",
"      Reentry and the development of cardiac arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10344?source=related_link\">",
"      Right bundle branch block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/42/26278?source=related_link\">",
"      The electrocardiogram in atrial fibrillation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_61_17371="Causes of fetomaternal transfusion";
var content_f16_61_17371=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F55779&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F55779&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Events thought to be associated with fetomaternal hemorrhage",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Delivery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Induced abortion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Spontaneous abortion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ectopic pregnancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Partial molar pregnancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chorionic villus sampling",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cordocentesis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Percutaneous fetal procedures (eg, fetoscopy)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Amniocentesis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        External cephalic version",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abruptio placenta",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antenatal hemorrhage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Maternal abdominal trauma (eg, motor vehicle accident, fall, assault)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Manual removal of the placenta",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     Fetal-maternal&nbsp;transfusion&nbsp;can also be&nbsp;idiopathic.&nbsp;",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_61_17371=[""].join("\n");
var outline_f16_61_17371=null;
var title_f16_61_17372="Duration of labor by parity";
var content_f16_61_17372=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F69170&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F69170&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Median and (95th percentile) hours for cervical dilation during labor by parity",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Cervical dilation",
"        <br/>",
"        (cm)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Parity 0",
"        <br/>",
"        (n = 25,624)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Parity 1",
"        <br/>",
"        (n = 16,755)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Parity 2+",
"        <br/>",
"        (n = 16,219)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3-4",
"       </td>",
"       <td>",
"        1.8 (8.1)",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4-5",
"       </td>",
"       <td>",
"        1.3 (6.4)",
"       </td>",
"       <td>",
"        1.4 (7.3)",
"       </td>",
"       <td>",
"        1.4 (7.0)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5-6",
"       </td>",
"       <td>",
"        0.8 (3.2)",
"       </td>",
"       <td>",
"        0.8 (3.4)",
"       </td>",
"       <td>",
"        0.8 (3.4)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6-7",
"       </td>",
"       <td>",
"        0.6 (2.2)",
"       </td>",
"       <td>",
"        0.5 (1.9)",
"       </td>",
"       <td>",
"        0.5 (1.8)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        7-8",
"       </td>",
"       <td>",
"        0.5 (1.6)",
"       </td>",
"       <td>",
"        0.4 (1.3)",
"       </td>",
"       <td>",
"        0.4 (1.2)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        8-9",
"       </td>",
"       <td>",
"        0.5 (1.4)",
"       </td>",
"       <td>",
"        0.3 (1.0)",
"       </td>",
"       <td>",
"        0.3 (0.9)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        9-10",
"       </td>",
"       <td>",
"        0.5 (1.8)",
"       </td>",
"       <td>",
"        0.3 (0.9)",
"       </td>",
"       <td>",
"        0.3 (0.8)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Second stage with epidural analgesia",
"       </td>",
"       <td>",
"        1.1 (3.6)",
"       </td>",
"       <td>",
"        0.4 (2.0)",
"       </td>",
"       <td>",
"        0.3 (1.6)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Second stage without epidural analgesia",
"       </td>",
"       <td>",
"        0.6 (2.8)",
"       </td>",
"       <td>",
"        0.2 (1.3)",
"       </td>",
"       <td>",
"        0.1 (1.1)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <p>",
"     &nbsp;",
"    </p>",
"    <div class=\"footnotes\">",
"     Note the 95th percentile for duration of time to dilate from 4 to 6 cm is almost 10 hours in nulliparous women.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Zhang J, Landy H, Ware Branch D, et al. Contemporary patterns of spontaneous labor with normal neonatal outcomes. Obstet Gynecol 2010; 116:1281. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_61_17372=[""].join("\n");
var outline_f16_61_17372=null;
var title_f16_61_17373="Dosing regimens for treatment of latent TB";
var content_f16_61_17373=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F65944&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F65944&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Dosing regimens for treatment of latent tuberculosis (see text for discussion of clinical approach to selecting a regimen for treatment of latent tuberculosis)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"20%\">",
"     </colgroup>",
"     <colgroup span=\"2\" width=\"40%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Adults",
"       </td>",
"       <td class=\"subtitle1\">",
"        Children &lt;12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"6\">",
"        <strong>",
"         Isoniazid",
"        </strong>",
"        *",
"       </td>",
"       <td class=\"sublist1_start\">",
"        Standard regimen:",
"       </td>",
"       <td class=\"sublist1_start\">",
"        Standard regimen:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        300 mg PO daily for nine months",
"       </td>",
"       <td class=\"indent1\">",
"        10 to 15 mg/kg PO daily for nine months; not to exceed 300 mg/day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Alternate regimens:",
"       </td>",
"       <td class=\"sublist1_start\">",
"        Alternate regimen:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        300 mg PO daily for six months",
"       </td>",
"       <td class=\"indent1\" rowspan=\"3\">",
"        20 to 30 mg/kg PO twice weekly for nine months",
"        <sup>",
"         &bull;",
"        </sup>",
"        ; not to exceed 900 mg/day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        900 mg PO twice weekly",
"        <sup>",
"         &Delta;",
"        </sup>",
"        for nine months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        900 mg PO twice weekly",
"        <sup>",
"         &Delta;",
"        </sup>",
"        for six months",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"8\">",
"        <strong>",
"         Isoniazid and rifapentine",
"        </strong>",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td class=\"sublist1_start\">",
"        Isoniazid (orally once weekly for 12 doses, given by direct observation)",
"       </td>",
"       <td class=\"sublist1_start\" rowspan=\"8\">",
"        (Further study needed)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        15 mg/kg, rounded up to the nearest 50 or 100 mg; 900 mg maximum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Rifapentine (orally once weekly for three months, given by direct observation)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        10 to 14 kg: 300 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        14.1 to 25 kg: 450 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        25.1 to 32 kg: 600 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        32.1 to 49.9 kg: 750 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &gt;50 kg: 900 mg maximum",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Rifampin",
"        </strong>",
"       </td>",
"       <td>",
"        600 mg PO daily for four months",
"       </td>",
"       <td>",
"        10 to 20 mg/kg PO daily for six months; not to exceed 600 mg/day",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        <strong>",
"         Isoniazid and rifampin",
"        </strong>",
"       </td>",
"       <td>",
"        Isoniazid 300 mg PO daily for three months",
"       </td>",
"       <td>",
"        Isoniazid 10 to 15 mg/kg PO daily for three months; not to exceed 300 mg/day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rifampin 600 mg PO daily for three months",
"       </td>",
"       <td>",
"        Rifampin 10 to 20 mg/kg PO daily for three months; not to exceed 600 mg/day",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Pyridoxine supplementation (25 to 50 mg PO daily for adults; 1 to 2 mg/kg PO daily for children &lt;12) should be considered for patients on prolonged isoniazid; this is especially important for patients with conditions that can predispose to neuropathy (including diabetes, uremia, alcoholism, malnutrition, and HIV infection), as well as in the setting of pregnancy and seizure disorders. In addition, pyridoxine should be administered to infants of breastfeeding mothers receiving isoniazid. Among children on isoniazid, pyridoxine is warranted for exclusively breastfed infants, children on meat- and milk-deficient diets, children with nutritional deficiencies, and symptomatic HIV-infected children.",
"     <br>",
"      <font class=\"bullet\">",
"       &bull;",
"      </font>",
"      Six-month regimens of isoniazid are not appropriate for children.",
"      <br>",
"       &Delta; Twice-weekly regimens must be administered with directly observed therapy (DOT).",
"       <br>",
"        <font class=\"lozenge\">",
"         &loz;",
"        </font>",
"        Patient categories for which this regimen has been studied, and patient categories for which this regiemn is NOT appropriate (until further data are available), are discussed in the text. (Refer to UpToDate topic on treatment of latent TB infection in HIV-negative adults, section on isoniazid and rifapentine).",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from:",
"     <br>",
"      <ol>",
"       <li>",
"        Blumberg HM, Leonard MK Jr, Jasmer RM. Update on treatment of tuberculosis and latent tuberculosis infection. JAMA 2005; 293:2776.",
"       </li>",
"       <li>",
"        Recommendations for Use of an Isoniazid-Rifapentine Regimen with Direct Observation to Treat Latent Mycobacterium tuberculosis Infection. MMWR 2011; 60(48):1650.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_61_17373=[""].join("\n");
var outline_f16_61_17373=null;
var title_f16_61_17374="Primary and second responses";
var content_f16_61_17374=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F71886&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F71886&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 501px\">",
"   <div class=\"ttl\">",
"    Primary and secondary antibody responses to tetanus and diphtheria antigens",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 481px; height: 349px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Antigen is administered at the time indicated on the X axis.&nbsp;Time on the&nbsp;X axis&nbsp;is not marked with units&nbsp;since the course of the response will vary greatly depending on the dose of antigen, the route of administration, and whether the antigen persists in the body or is rapidly cleared. For many protein or glycoprotein antigens not associated with an ongoing infection, the time course of the response ranges from two to four weeks. In the primary response, there is an initial lag period, and then IgM is produced initially, followed later by IgG.&nbsp; In the&nbsp;secondary response, there is a&nbsp;much shorter lag period. The initial rise in antibody production is more rapid, and the total amount produced is greater than in the&nbsp;primary response. In addition, there is a predominance of the IgG isotype (although IgM antibodies are produced as well), and the antibodies have higher affinity for antigen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Legend is&nbsp;modified with permission from: Bona, C, Bonilla, F. B Cells and Humoral Immunity. In: Textbook of Immunology, second edition, Harwood Academic Publishers 1996. Page 124, figure 5.I4.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_61_17374=[""].join("\n");
var outline_f16_61_17374=null;
var title_f16_61_17375="Uterus didelphys normal vagina";
var content_f16_61_17375=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F77029&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F77029&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Uterus didelphys, bicollis, with normal vagina",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 348px; height: 284px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Pediatric and Adolescent Gynecology, 6th ed, Emans SJ, Laufer MR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_61_17375=[""].join("\n");
var outline_f16_61_17375=null;
